J. Douglas Rizzo MD, MS Curriculum Vitae CV

Date of Document: October 21, 2021

CURRICULUM VITAE

J. Douglas Rizzo MD, MS

Director, Center Associate Director, ProfessorDepartment of Medicine

Division of Hematology and Oncology - MedicineSenior Scientific Director

Center for International Blood and Marrow Transplant Research (CIBMTR)And

Associate Director of Clinical OperationsFroedtert & the Medical College of Wisconsin Cancer Center

Cancer Service Line DirectorAnd

Professor of MedicineBlood and Marrow Transplantation Program

Medical College of Wisconsin

OFFICE ADDRESS: Clinical Cancer Center9200 W Wisconsin AveMilwaukee, WI 53226Phone: 414-805-0678Fax: 414-805-0714Email: [email protected]

EDUCATION: 09/1982 - 06/1986 B.S., Virginia Polytechnic Institute and State University, Blacksburg, VA09/1986 - 09/1990 M.D., Johns Hopkins University School of Medicine, Baltimore, MD05/2005 M.S. Epidemiology, Medical College of Wisconsin, Milwaukee, WI

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: 07/1990 - 06/1993 Resident, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA07/1994 - 06/1998 Senior Clinical Fellow, Department of Oncology, Johns Hopkins University School of

Medicine, Baltimore, MD07/1995 - 06/1998 Senior Clinical Fellow, Department of Hematology, Johns Hopkins University School of

Medicine, Baltimore, MD07/1996 - 06/1998 Robert Wood Johnson Clinical Scholars Program, Johns Hopkins University School of

Medicine, Baltimore, MD

FACULTY APPOINTMENTS: 07/1991 - 06/1993 Assistant Instructor, Medicine, Hospital of the University of Pennsylvania, Philadelphia,

PA07/1993 - 06/1994 Staff Internist, Internal Medicine Practice, Wilkens Avenue MedicalCenter, IPA,

Baltimore, MD09/1993 - 06/1996 Secondary Clinical Staff, Emergency Medicine, Johns Hopkins Bayview Medical Center,

Baltimore, MD07/1998 - 05/2003 Assistant Scientific Director, International Bone Marrow Transplant Registsry, Autologous

Blood and Marrow Transplant Registry, Medical College of Wisconsin, Milwaukee, WI07/1998 - 05/2003 Assistant Professor of Medicine, Division of Neoplastic Diseases, Medical College of

Wisconsin, Milwaukee, WI

1 / 30

06/2003 - 06/2008 Associate Professor of Medicine, Department of Medicine, Division of NeoplasticDiseases and Related Disorders, Medical College of Wisconsin, Milwaukee, WI

06/2003 - 12/2013 Associate Scientific Director, Department of Medicine, CIBMTR, Medical College ofWisconsin, Milwaukee, WI

07/2005 - 10/2006 Acting Clinical Director, Inpatient Hematopoietic Cell Transplant Program, MedicalCollege of Wisconsin, Milwaukee, WI

07/2008 - Present Professor of Medicine, Department of Medicine, Division of Hematology and Oncology(with Tenure), Medical College of Wisconsin, Milwaukee, WI

11/2012 - Present Associate Director of Clinical Operations for Froedtert & the Medical College ofWisconsin Cancer Center; Cancer Service Line Director, Froedtert & the Medical College ofWisconsin, 9200 West Wisconsin Avenue, Suite C5500, Milwaukee, WI 53226

01/2014 - Present Senior Scientific Director, Department of Medicine, CIBMTR, Medical College ofWisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS: 1995 - 1996 Coordinator, Oncology Center Journal Club Instructor, Medical Student Clinical Skills Course

Johns Hopkins University School of Medicine, Baltimore, MD2002 - Present Member, Fellowship Committee, Medical College of Wisconsin, WI, Division of Hematology

and Oncology, Milwaukee, WI2010 - 2013 Member Representative for the Faculty Council, Department of Medicine, Medical College of

Wisconsin, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES: 07/1993 - 06/1994 St. Agnes Hospital, Baltimore, MD09/1993 - 10/1996 Johns Hopkins Bayview Medical Center, Baltimore, MD07/1998 - Present Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Avenue, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:

Board Certified Issue Date ExpirationAmerican Board of Internal

Medicine09/1993 09/2003

ABIM - Medical Oncology 11/1998 11/2008ABIM - Hematology 11/1999 11/2009ABIM - Medical Oncology -

Maintenance of certification02/2012 12/2022

Licensure Number Issue Date ExpirationPennsylvania Internal

Medicine (Inactive)MD-047878-L 1992 None

Maryland Internal Medicine(Inactive)

D44529 1993 None

Wisconsin InternalMedicine (Active)

39926 1998 None

AWARDS AND HONORS: 04/1986 Virginia Tech Man of the Year, Outstanding Student in the College of Arts and Sciences04/1996 Virginia Tech Outstanding Young Alumnus

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: 1993 - Present American College of Physicians1996 - Present American Society of Hematology1997 - Present American Society of Clinical Oncology2002 - Present American Society for Blood and Marrow Transplantation

2 / 30

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: Editorship

2003 - 03/2005 Contributing Editor, ASH News Journal Review

Scientific Reviewer, Biology Blood and Marrow Transplantation Scientific Reviewer, Journal of Clinical Oncology Scientific Reviewer, Bone Marrow Transplantation Scientific Reviewer, Blood

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: 12/1997 - 11/2000 Member, Committee on Optimization of Hematologic Care, American Society of

Hematology12/2000 - 11/2002 Chair, Committee on Optimization of Hematologic Care, American Society of

Hematology10/2001 - 10/2004 Member, American Society of Hematology Clinical Research Training Institute Task

Force12/2001 - 12/2005 Consultant, Data Safety Monitoring Board, Antigenics, Inc. A multi-center, randomized

phase III study of adjuvant Oncophage versus observation in patients with high-risk of recurrence aftersurgical treatment of renal cell carcinoma

06/2002 - 02/2012 Member, Evidence-Based Review Steering Committee, American Society for Blood andMarrow Transplantation

10/2002 - 05/2003 Member, Task Force on Quality Care and Clinical Issues, American Society ofHematology

12/2002 Invitee, Task Force to Determine Optimal Clinical Trials to Evaluate Erythropoietins, ClinicalInvestigations Branch, National Cancer Institute

12/2002 - 12/2006 Member, Committee on Government Affairs, American Society of Hematology02/2003 - 06/2005 Invited Faculty/Mentor, Clinical Research Training Institute, American Society of

Hematology04/2003 - 12/2004 Reviewer, ASH Clinical Scholar Award Study Section, American Society of Hematology2003 - 2005 Expert Advisor, Technical Expert Panel, Blue Cross Blue Shield Association06/2004 - 06/2005 Invited Member, NIH Chronic GVHD Consensus Development Project, National Institutes

of Health10/2004 - 11/2007 Co-Chair, ASH/ASCO Erythropoietin stimulants guideline (II) panel, American Society of

Hematology/American Society of Clinical Oncology2005 Expert Advisor, Evidence-Based Practice Center Sytematic Review. “Effectiveness of Epoietin and

Darbepoietin for Managing Anemia in Patients Undergoing Cancer Treatment”01/2006 - Present Member, ASBMT Committee on Standardization of Outcomes Reporting and RFIs,

American Society for Blood and Marrow Transplantation04/2006 - Present Member, ASBMT Quality Outcomes Committee, American Society for Blood and Marrow

Transplantation08/2007 Invited Faculty/Mentor, Clinical Research Training Institute, American Society of Hematology12/2007 - 12/2012 Member, ASH Subcommittee on Quality of Care, American Society of Hematology03/2011 - 07/2016 Member, ASH and College of American Pathologists Acute Leukemia Workup Guideline

Development Panel, American Society of Hematology2011 - 2017 Physician Consultant, OptumHealth Bone Marrow/Stem Cell Transplant Expert Panel2011 - 2012 Expert Panelist, Center Outcomes Reporting, Blue Cross Blue Shield05/2012 - 06/2013 Member, ASH Quality Task Force, American Society of Hematology06/2012 - 06/2014 Member, Medicare Evidence Development & Coverage Advisory Committee, MEDCAC01/2014 - Present Member, FACT Clinical Outcomes Task Force08/2015 - 07/2016 Member, NIH Blood and Marrow Transplant Late Effects Workgroup, NIH

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

ActivePeer Review

Title: Stem Cell Therapeutic Outcomes

3 / 30

Database (HHSH25020170006C)Source: U.S. Department of Health and Human

Services Health Resources and ServicesAdministration

Role: Project Director (PI)PI: J. Douglas Rizzo, MD, MSDates: 09/27/2017 - 09/26/2022Direct Funds: $18,608,009

Title: Identification of a Molecular Biomarker

for Social Disparities in CancerOutcomes (2 year award with third yearprovisional)

Source: Clinical and Translational ScienceInstitute Mentored Career Development(KL2) Award, supported by grantULTR001436 and KL2TR001438 fromthe Clinical and Translational ScienceAward (CTSA) program of the NCATS

Role: Primary MentorPI: Jennifer M. Knight, MD, MS, FAPMDirect Funds: $255,000

PendingPeer Review

Title: Using HL7 FHIR to exchangeHematopoietic Cell Transplant andCellular Therapy data to support cancerresearch

Source: NIH/NCIPI: J. Douglas Rizzo, MD, MSDates: 07/01/2018 - 06/23/2023Direct Funds: $3,538,378

PriorPeer Review

Title: Breast Cancer ResearchSource: Medical College of WisconsinRole: Principal InvestigatorPI: J. Douglas Rizzo, MD, MSDates: 01/01/1999 - 03/31/2001Direct Funds: $15,000

Title: Long-Term Outcome of Blood and

Marrow Transplantation(K23-CA-82350)

Source: National Institutes of Health, NationalCancer Institute

Role: Principal InvestigatorPI: J. Douglas Rizzo, MD, MSDates: 09/03/1999 - 06/30/2004Direct Funds: $663,019

Title: Assessment of Policies and Practices for

Reducing Opportunistic Infections

4 / 30

among BMT RecipientsSource: Centers for Disease ControlRole: Co-Principal InvestigatorDates: 09/07/1999 - 11/07/1999Direct Funds: $13,378

Title: Zenepax as Primary Treatment for Acute

Graft-Versus-Host DiseaseSource: RocheRole: Site Principal InvestigatorDates: 02/17/2000 - 09/01/2004Direct Funds: $79,464

Title: Data Resource for Analyzing Blood and

Marrow Transplants: Stem CellTransplant Center Factors

Source: Agency for Healthcare Research &Quality

Role: Co-InvestigatorDates: 01/01/2002 - 12/31/2003Direct Funds: $66,667

Title: Assessment of Health State Utilities in

Hematopoietic Stem Cell TransplantSurvivors

Source: Lance Armstrong FoundationRole: Co-InvestigatorDates: 01/01/2004 - 12/31/2004Direct Funds: $21,455

Title: A Public System for Electronic

Exchange of Clinical Network Data: ACollaborative Effort of the InternationalBone Marrow Transplant Registry andthe National Marrow Donor Foundation

Source: National Institutes of Health/NationalHeart, Lung & Blood Institute(subcontract with the National MarrowDonor Program)

Role: Co-InvestigatorDates: 09/30/2004 - 09/29/2007Direct Funds: $315,463





Title: A Data Resource for Analyzing Blood

and Marrow Transplants (U24CA76518)

Source: National Institutes of Health/National

5 / 30

Cancer InstituteRole: Co-InvestigatorPI: Mary M. Horowitz, MD, MSDates: 03/01/2008 - 02/28/2013Direct Funds: $12,881,026

Title: RDSafe: A Multiinstitutional Study of

HSC Donor Safety and Quality of Life(1R01-HL085707-01A1)

Source: National Institutes of Health/NationalHeart, Lung & Blood Institute(subcontract with University of UtahSchool of Medicine)

Role: Co-Principal InvestigatorPI: Michael Pulsipher, MDDates: 12/01/2008 - 11/30/2013Direct Funds: $117,308





Title: Pilot study using propranolol to decrease

gene expression of stress-mediated beta-adrenergic pathways in hematopoieticstem cell transplant recipients

Source: Leidos Biomed/NCI Network onBiobehavioral Pathways in Cancer; NCIContract No. HHSN261200800001E

Role: Co-InvestigatorPI: Jennifer M. Knight, MD, MS, FAPMDates: 03/23/2015 - 09/30/2016Direct Funds: $48,916

INVITED LECTURES/WORKSHOPS/PRESENTATIONS: LocalRizzo JD, Stem Cell Transplant Basics, IBMTR Data Management Workshop, Milwaukee, WI, 11/1998Rizzo JD, Basics of BMT, IBMTR Data Management Workshop, Milwaukee, WI, 10/1999Rizzo JD, Diagnosis and Management of Hypereosinophilia Syndrome, Department of Medicine Grand

Rounds, Medical College of Wisconsin, 03/2000Rizzo JD, Conditioning Regimens for Transplantation, IBMTR Data Management Workshop, Milwaukee,

WI, 09/2000Rizzo JD, Introduction to BMT, IBMTR Data Management Workshop, Milwaukee, WI, 09/2001Rizzo JD, Lymphoma Overview, IBMTR Data Management Workshop, Milwaukee, WI, 09/2001Rizzo JD, Follow-up Begins Pre-Transplant, IBMTR Data Management Workshop, Milwaukee, WI, 09/2002Rizzo JD, Early and Late Complications of HSCT, Hematology/Oncology Fellowship Lecture Series,

Milwaukee, WI, 10/2002Rizzo JD, Early and Late Complications of HSCT, Hematology/Oncology Fellowship Lecture Series,

Milwaukee, WI, 10/2003Rizzo JD, ESAs in Patients with Cancer, Department of Medicine, Grand Rounds, Milwaukee, WI, 05/2009

6 / 30

Rizzo, JD, CIBMTR Update, Invited oral presentation for the 2012 Fall Clinical Research Professional's DataManagement (CRP/DM) Conference, Milwaukee, WI, 10/2012

Local and national lectures for HCT clinical research associate conferences averaging more than 5 lecturesannually not listed beyond 2003 for brevity

NationalRizzo JD, Tunis S, Bass EB, Technology Assessment for Genetic Testing for BRCA-1 and BRCA-2,

Technology Assessment Committee of Blue Cross Blue Shield of Maryland, Baltimore, Maryland,05/1997

Rizzo JD, Vogelsang GB, Outcomes Measures in Hematologic Malignancies, Johns Hopkins Fifth AnnualProgress in Hematologic Malignancies and Bone Marrow Transplantation, Baltimore, Maryland,09/1997

Rizzo JD, Second cancers workshop, Tandem BMT Meetings, Keystone, Colorado, 02/1999Rizzo JD, Second cancers after transplantation, Roundtable, Tandem BMT Meetings, Anaheim, California,

03/2000Rizzo JD and Lichtin AE (Moderators), Health Services and Outcomes Research Simultaneous sessions,

American Society of Hematology, Orlando, Florida, 12/2001Rizzo JD (Chair), Bennett C, Seidenfeld J, Lichtin AE, Red Cells III: Erythropoietin: a paradigm for the

development of practice guidelines, American Society of Hematology, Orlando, Florida, 12/2001Rizzo JD, Late sequelae of BMT: new neoplastic complications. International Concurrent session, Tandem

BMT Meetings, Orlando, Florida, 02/2002Rizzo JD, Follow-up begins pretransplant, Clinical Research Associates Data Management Conference,

Tandem BMT Meetings, Keystone, CO, 01/2003Rizzo JD, Chair, Transplant center resources, Concurrent Scientific Sessions, Tandem BMT Meetings,

Keystone, CO, 02/2003Rizzo JD, Red tired, Oral Abstract Discussant, 39th Annual Meeting of the American Society of Clinical

Oncology, Chicago, IL, 06/2003Rizzo JD, How do age and weight affect outcome after stem cell transplantation?, Oral Abstract Discussant,

39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 06/2003Rizzo JD, Medical Record Interpretation, Tandem BMT Meetings, Orlando, FL, 02/2004Rizzo JD, New malignancies after hematopoietic stem cell transplantation, Tandem BMT Meetings, Orlando,

FL, 02/2004Rizzo JD: Socie G, Workshop to develop Recommendations for Post-transplant Screening and Prevention,

Tandem BMT Meetings, Orlando, FL, 02/2004Rizzo JD, Post HSCT/DCI-Disease response over time, Clinical Research Professionals Data Management

Conference, Minneapolis, MN, 11/2005Rizzo JD, CIBMTR and Patient Advocacy, HRSA Patient Advocacy Conference, invited participant,

Rockville, MD, 11/2005Rizzo JD, Requirements for the Stem Cell Therapeutics Outcomes Database. Oral presentation during

Concurrent Scientific Session, Tandem BMT Meetings, Keystone, CO, 02/2007Rizzo JD, What are the new requirements for the SCTOD?, Invited oral presentation for ASBMT Medical

Directors Conference, Keystone, CO, 02/2007Rizzo JD, What are the data requirements for the SCTOD?, Invited oral presentation for BMT Center

Administrators Conference, Keystone, CO, 02/2007Rizzo JD, Late Effects Post Transplant: Recommended screening and preventive practices, Invited oral

presentation for BMT Pharmacists Conference, Keystone, CO, 02/2007Rizzo JD, Invited participant, National Heart, Lung and Blood Institute’s Technology and Data Standards

Initiative Workshop, Bethesda, MD, 05/2007Rizzo JD, Invited Participant, Blood and Marrow Transplant Clinical Trials Network State of the Science

Symposium, Ann Arbor, MI, 06/2007Rizzo JD, Silver S, Briefing on the use of ESAs for Cancer Patients, Invited speaker, Presentation to the

House Ways and Means Committee/Congressional Health staffers, Rayburn Office Building,Washington DC, 10/23/2007

Rizzo JD, Jones R, Conference developer, planners and co-facilitators for 150 data and IT personnelregarding new initiatives for collecting and reporting data to the SCTOD, ASBMT/CIBMTR/NMDPInformation Technology Summit, Minneapolis, MN, 01/18/2008 - 01/19/2008

Rizzo JD, SCTOD update: Where are we now, and where are we headed?, ASBMT Medical Directors

7 / 30

Conference, San Diego, CA, 02/2008Rizzo JD, Chair, Education Session: Erythropoiesis-Stimulating Agents in Cancer Chemotherapy: Recent

Developments and Clinical Implications. “ESAs, What do we really know”, Invited speaker, AmericanSociety of Clinical Oncology Annual Meeting, Chicago, IL, 05/30/2008

Rizzo JD, Conference developer, planner and chair, Center Specific Outcomes in HCT Forum, Milwaukee,WI, 09/2008

Rizzo JD, LeMaistre CF, Jones RB, Center-Specific Outcomes Analysis and Reporting – What is Next?,Invited oral presentation for BMT Medical Directors Conference, Tampa, FL, 02/2009

Rizzo JD, Jones RB, SCTOD Update, Invited oral presentation for BMT Center Administrators Conference,Tampa, FL, 02/2009

Rizzo JD, SCTOD/AGNIS Update, Invited oral presentation for Clinical Research Professionals DataManagement Conference, Tampa, FL, 02/2009

Rizzo JD, Optimizing CIBMTR Data Reporting, Invited oral presentation at the Annual InternationalUmbilical Cord Blood Transplantation Symposium, Manhattan Beach, CA, 06/2009

Rizzo JD, Jones RB, SCTOD Update, Invited oral presentation for BMT Center Administrators Conference,Orlando, FL, 02/2010

Rizzo JD, Update on Coverage with Evidence Development for Medicare MDS Patients, Invited oralpresentation for BMT Medical Directors Conference, Honolulu, HI, 02/2011

Rizzo JD, Jones RB, SCTOD Update, Invited oral presentation for BMT Center Administrators Conference,Honolulu, HI, 02/2011

Rizzo JD, Post Transplant Survivorship Issues, Invited oral presentation for Transplant Medicine in BloodCancers Conference, Madison, WI, 04/2011

Rizzo JD, Bone Marrow Transplantation and MDS, Coverage with Evidence, Invited oral presentation forASH/ASCO Carrier Advisory Committee Network Meeting, Alexandria, VA, 07/2011

Rizzo JD, What Can We Learn From Other Experiences?, Invited oral presentation for Consensus Conferenceon Transplant Program Quality and Surveillance, Sponsored by the Scientific Registry of TransplantRecipients, Arlington, VA, 02/2012

Rizzo JD, SCTOD Update, Invited oral presentation for BMT Center Administrators Conference, BMTTandem Meetings, San Diego, CA, 02/2012

Rizzo JD, Update: 2011 Late Effects Monitoring Recommendations, Invited oral presentation for BMTConference, BMT Tandem meetings, San Diego, CA, 02/2012

Rizzo, JD, Survivorship for the Recipient of HCT for Multiple Myeloma, Invited oral presentation for the10th Annual Multiple Myeloma Conference, Sponsored by the Leukemia & Lymphoma Society,Sheboygan, WI, 09/2012

Rizzo, JD, Secrets of a Great Talk: How to Create and Deliver Effective Presentations, Invited oralpresentation for the Trade Secrets of a Successful Academic Session for the 54th American Society ofHematology Annual Meeting and Exposition, Atlanta, GA, 12/2012

Rizzo, JD, CIBMTR Update: Clinical Research Professionals/Data Management Conference, Invited oralpresentation for the BMT Tandem Meetings, Salt Lake City, UT, 02/2013

Rizzo, JD, How Programs and Health Plans are Using Data to Improve Program Performance and BeyondElectronic Data Capture to Data Sharing, Invited oral presentation for the BMT Center AdministratorsConference, BMT Tandem Meetings, Salt Lake City, UT, 02/2013

Rizzo, JD, Quality, Transparency, and Patient Safety in BMT, Invited oral presentation for the Blood andMarrow Stem Cell Transplant: A Forum on Quality, Transparency, Cost & Value, Chicago, IL,07/2013

Rizzo, JD, Data from CIBMTR: How You Can Use It., Invited oral presentation for BMT Tandem Meetings,Dallas, TX, 02/2014

Rizzo, JD, How Can We Overcome the Current Barriers to Transplantation? ASBMT President's Conference,Invited oral presentation for BMT Tandem Meetings, Dallas, TX, 03/2014

Rizzo, JD, CIBMTR Data Highlights, Center Volumes and Center Outcomes Reporting in HCT, Invited oralpresentation for the Clinical Research Professional/Data Management Conference, BMT Tandemmeetings, San Diego, CA, 02/2015

Rizzo, JD, Center Outcomes Reporting in HCT: Recommendations from the Center Outcome Forum 2014,Invited oral presentation for the BMT Center Administrators Conference, BMT Tandem meetings, SanDiego, CA, 02/2015

Rizzo, JD, Quality Measurement in HCT, Invited oral presentation for the Aligning Quality and Value inHCT meeting, Minneapolis, MN, 07/15/2015

8 / 30

Rizzo, JD, Transplant Center Specific Outcomes Analysis - Generation and Use, Invited oral presentation forthe NMDP Council Meeting 2015, Minneapolis, MN, 11/06/2015

Rizzo, JD, Center Specific Survival Analysis Methods, Invited oral presentation for the BMT CenterAdministrators Conference, BMT Tandem meetings, Honolulu, HI, 02/2016

Rizzo, JD, Center Specific Outcomes Reporting: How can CIBMTR help centers' performance improvementefforts?, Annual Sarah Cannon Blood Cancer Network meeting, Denver, Colorado, 09/12/2016

Rizzo, JD, Update on CIBMTR's response to CMS' Coverage with Evidence Development (CED) for BloodStem Cell Transplantation Indications, Invited lecture for the HHS Advisory Council on Blood StemCell Transplantation (ACBSCT), Arlington, Virginia, 09/13/2016

Rizzo, JD, Measuring Quality of Life, Implementing Quality & Value in HCT, Minneapolis, Minnesota,10/19/2016 - 10/20/2016

Rizzo, JD, Vaule-Based Purchasing and Access, Implementing Quality & Value in HCT, Minneapolis,Minnesota, 10/19/2016 - 10/20/2016

Rizzo, JD, Quality Improvement in HCT, Implementing Quality & Value in HCT, Minneapolis, Minnesota,10/19/2016 - 10/20/2016

Rizzo, JD, CIBMTR Data Life Cycle, Invited oral presentation for BMT Tandem Meetings, Kissimmee,Florida, 02/21/2017

Rizzo, JD, CIBMTR Update, Invited oral presentation for BMT Center Administrative Director SIG Meeting,BMT Tandem Meeting, Kissimmee, Florida, 02/23/2017

Rizzo, JD, CIBMTR Data Life Cycle, Invited oral presentation for BMT Tandem Meetings, Clinical ResearchProfessionals Session, Salt lake City, UT, 02/20/2018

Rizzo, JD, CIBMTR Center Specific Analysis Update, Invited oral presentation for BMT CenterAdministrative Director SIG Meeting, BMT Tandem Meeting, Salt lake City, UT, 02/22/2018

Rizzo, JD, See It to Believe It: CIBMTR Enhanced Data Back to Center (eDBtC) and Center PerformanceApplications to Visualize Program Data, Invited oral presentation for BMT Tandem Meetings, Saltlake City, UT, 02/23/2018

InternationalSluiters JF, Schalekamp L, Dirks I, Rizzo JD, Cryptosporidium parvum antibodies in normal healthy blood

donors, VIth European Multicolloquium of Parasitology, The Hague, Netherlands, 1992Rizzo JD, Center specific outcome reporting for HCT in the United States, Swiss Blood Stem Cells JACIE

Conference, Berne, Switzerland, 11/2009Rizzo JD, Current Indications for HCT, Workshop of the Worldwide network for Blood and Marrow

Transplantation (WBMT) in collaboration with the WHO, Hanoi, Vietnam, 11/2011Rizzo JD, Screening and prevention of Late Effects., EBMT Late Effects Working Party Education Day,

Barcelona, Spain, 11/2011Rizzo JD (Session Chair/Moderator), Establishing a Transplant Program., Workshop of the Worldwide

network for Blood and Marrow Transplantation (WBMT) in collaboration with the WHO., Hanoi,Vietnam, 11/2011

Rizzo, JD, Benefits and Challenges of the Stem Cell Act on HCT in the United States, Invited lecture for theJapanese Office of the Ministry of Health, Labor and Welfare, Tokyo, Japan, 01/2013

Rizzo JD, Implications of the Stem Cell Act and the Stem Cell Therapeutic Outcomes Database on HCT inthe United States, Invited lecture to the Japanese Society for HCT, Tokyo, Japan, 01/2013

Rizzo JD, Value of Outcomes Registries in HCT, Invited lecture for the EMBMT Data ManagementWorkshop for Hematopoietic Stem Cell Transplantation (HSCT) Centers, Tunis, Tunisia, 11/2014

Rizzo JD, Clinical Outcome Reporting: The US experience of the Stem Cell Therapeutic Outcomes Database(SCTOD)., Invited lecture for the EBMT 41st Annual Meeting of the European Society of Blood andMarrow Transplantation,, Istanbul, Turkey, 03/2015

Rizzo, JD, Care From a Distance, Invited lecture for the CBMTG 2016 Annual Conference, Vancouver,British Columbia, Canada, 04/26/2016

Rizzo, JD, Data and Center Specific Survival Analysis CIBMTR, Invited lecture for the 20th Congress of theBrazilian Society of Bone Marrow Transplantation, Fortaleza, Ceara, Brazil, 08/24/2016 - 08/27/2016

Rizzo, JD, Quality of life, support and late effects in Bone Marrow Transplants, 20th Congress of theBrazilian Society of Bone Marrow Transplantation, Fortaleza, Ceara, Brazil, 08/24/2016 - 08/27/2016

COMMITTEE SERVICE:

9 / 30

Medical College of Wisconsin2000 - 2003 Health Policy Institute Representative, Faculty Council, Medical College of Wisconsin2003 - 2004 Faculty Benefits Committee,, Faculty Council, Medical College of Wisconsin2010 Member, MCW Tissue Bank Executive Committee, Medical College of Wisconsin2010 - 2011 Appointed Member, Research Data Security Task Force, Medical College of Wisconsin2010 - 2013 Member, Representative for the Faculty Council, Medicine, Medical College of Wisconsin2011 - 2012 Appointed Member, President and Dean's IT Advisory Committee, Medical College of

Wisconsin2011 - 2013 Appointed Physician Champion, EPIC Oncology Solutions Implementation,

Hematology/Oncology, Medical College of Wisconsin2012 - Present Member, Joint Strategic Planning Committee, Froedtert and the Medical College of

Wisconsin2012 - Present Member, Medical College Physicians Workforce Planning Committee, Medical College of

Wisconsin2013 Member, Service Line Planning Committee, Froedtert and the Medical College of Wisconsin2013 Member, Chief Medical Officer-Enterprise Search Committee, Froedtert and the Medical College of

Wisconsin2015 Member, Medical College of Wisconsin Chair of Radiation Oncology Search Committee, Medical

College of Wisconsin

MEDICAL COLLEGE TEACHING ACTIVITIES: Resident and Fellow Education

10/2002 Post-transplant toxicities, Fellow Education Lecture01/2003 Basics of BMT, Resident Education Lecture07/2003 BMT for the Internist, Resident Education Lecture02/2004 Post-transplant toxicities, Fellow Education Lecture07/2004 BMT for the Internist, Resident Education Lecture01/2005 Overview of BMT, Fellow Education Lecture - annually

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED: Medical Students

Derek Serna, Medical College of Wisconsin, 05/2001 - 05/2005 M.D. CandidateMichael Rosenblum, M.S., Medical College of Wisconsin, 01/2002 - 05/2004 M.D., Ph.D. CandidateNan Wu, Medical College of Wisconsin, 2007 Summer Research Trainee

Graduate Students

PhD CommitteesJing Tao Wu, Medical College of Wisconsin, 07/1999 - 05/2001 Biostatistics Ph.D.

Thomas Joshua, Medical College of Wisconsin, 01/2005 - 12/2006Melissa B. Warden, Medical College of Wisconsin, 09/2005 - 05/2007

Faculty

Fausto Loberiza, M.D., M.S., Medical College of Wisconsin, 01/2001 - 12/2004Tasleem Raza, M.D., Medical College of Wisconsin, 01/2002 - 05/2005Parameswaran Hari, M.D., Medical College of Wisconsin, 05/2005 - 05/2006Tim Fenske, M.D., Medical College of Wisconsin, 07/2005 - 06/2008Jennifer Knight, M.D., Medical College of Wisconsin, 07/2011 - Present MCW Clinical Research Scholars

ProgramMaheen Abidi, M. D., Medical College of Wisconsin, 01/2014 - 06/2016 Infectious Diseases (mentoring

committee)

PROGRAMMATIC DEVELOPMENTS: Educational Programs

10 / 30

Faculty2003 - 2004 MCW Faculty Leadership Development Program, collaboration of MCW with University

of Wisconsin Milwaukee Business Administration Program. Intensive leadership development course 10/11/2015 - 10/23/2015 Leadership Development for Physicians in Academic Health Centers, Harvard

T.H. Chan School of Public Health

ABSTRACT REVIEWER AND PROGRAM COMMITTEE: 2002 American Society of Hematology Annual Meeting, Health Services Research Category 2005 American Society of Hematology Annual Meeting, Clinical Care-Recurrence, Secondary Neoplasia, and

Late Complications after Transplantation 2007 American Society of Hematology Annual Meeting, Session Moderator, Autologous Transplantation for

Myeloma 2008 American Society of Clinical Oncology Annual Meeting, Education Session Chair, Update on the use of

Erythroid Stimulants

BIBLIOGRAPHYRefereed Journal Publications/Original Papers1. Rizzo JD, Rowe SA. Meningism in a ten-month-old infant during OKT3 therapy. J Heart Transplant. 1990

Nov-Dec;9(6):727-8. 2. SundarRaj N, Rizzo JD, Anderson SC, Gesiotto JP. Expression of vimentin by rabbit corneal epithelial cells

during wound repair. Cell Tissue Res. 1992 Feb;267(2):347-56. 3. Rizzo JD, Strom BL, Berlin J. Replacement of central vascular catheters. N Engl J Med. 1993 Feb

11;328(6):445-6. 4. Rizzo JD, Powe NR. Methodological hurdles in conducting pharmacoeconomic analyses.

Pharmacoeconomics. 1999 Apr;15(4):339-55. 5. Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-based bone marrow

transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol. 1999Sep;17(9):2811-8.

6. Rizzo JD, Seidenfeld J, Piper M, Aronson N, Lichtin A, Littlewood TJ. Erythropoietin: a paradigm for thedevelopment of practice guidelines. Hematology Am Soc Hematol Educ Program. 2001:10-30.

7. Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA,Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR. Analysis of risk factors for thedevelopment of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABOincompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant. 2001;7(11):620-30.

8. Lazarus HM, Loberiza FR Jr, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, FreytesCO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA,Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM. Autotransplants forHodgkin's disease in first relapse or second remission: a report from the autologous blood and marrowtransplant registry (ABMTR). Bone Marrow Transplant. 2001 Feb;27(4):387-96.

9. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM, IBMTR Statistical Center ofthe International Bone Marrow Transplant Registry, Medical College of Wisconcin, Milwaukee, WI,USA, EBMT, Kiel, Germany. Peripheral blood stem cell donation: an analysis from the InternationalBone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant(EBMT) databases. Bone Marrow Transplant. 2001 Apr;27(7):689-92.

10. Horowitz MM, Loberiza FR, Bredeson CN, Rizzo JD, Nugent ML. Transplant registries: guiding clinicaldecisions and improving outcomes. Oncology (Williston Park). 2001 May;15(5):649-59; discussion663-4, 666.

11. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the resultsof bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001Nov;28(10):909-15.

12. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the resultsof bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant. 2001

11 / 30

Dec;28(11):1001-11. 13. Rizzo JD, Elias AD, Stiff PJ, Lazarus HM, Zhang MJ, Oblon DJ, Pecora AL, Hale GA, Horowitz MM.

Autologous stem cell transplantation for small cell lung cancer. Biol Blood Marrow Transplant.2002;8(5):273-80.

14. Loberiza FR Jr, Rizzo JD, Bredeson CN, Antin JH, Horowitz MM, Weeks JC, Lee SJ. Association ofdepressive syndrome and early deaths among patients after stem-cell transplantation for malignantdiseases. J Clin Oncol. 2002 Apr 15;20(8):2118-26.

15. Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, Davies SM, Lazarus HM, Bredeson CN,Marks DI, Canals C, Boogaerts MA, Goldman J, Champlin RE, Keating A, Weisdorf DJ, de Witte TM,Horowitz MM. Bone marrow transplantation from HLA-identical siblings as treatment formyelodysplasia. Blood. 2002 Sep 15;100(6):1997-2004.

16. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, JakubowskiAA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS, American Society ofClinical Oncology. American Society of Hematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the AmericanSociety of Hematology. J Clin Oncol. 2002 Oct 01;20(19):4083-107.

17. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, JakubowskiAA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS, American Society ofClinical Oncology, Americcan Society of Hematology. Use of epoetin in patients with cancer:evidence-based clinical practice guidelines of the American Society of Clinical Oncology and theAmerican Society of Hematology. Blood. 2002 Oct 01;100(7):2303-20.

18. Loberiza FR Jr, Serna DS, Horowitz MM, Rizzo JD. Transplant center characteristics and clinical outcomesafter hematopoietic stem cell transplantation: what do we know? Bone Marrow Transplant. 2003Mar;31(6):417-21.

19. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, López-Guillermo A, Gisselbrecht C, Guilhot F,Vose JM, van Biesen K, Rizzo JD, Weisenburger DD, Isaacson P, Horowitz MM, Goldstone AH,Lazarus HM, Schmitz N. Outcome of autologous transplantation for mantle cell lymphoma: a study bythe European Blood and Bone Marrow Transplant and Autologous Blood and Marrow TransplantRegistries. Br J Haematol. 2003 Mar;120(5):793-800.

20. Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S, Fay JW, Freytes CO, Goldstein SC,Herzig RH, Keating A, Miller CB, Nevill TJ, Pecora AL, Rizzo JD, Williams SF, Li CY, Travis LB,Weisdorf DJ. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation forlymphoma: a multicenter case-control study. Blood. 2003 Mar 01;101(5):2015-23.

21. Rosenblum MD, Bredeson CN, Chang CC, Rizzo JD. Subcutaneous plasmacytomas with tropism to sites ofprevious trauma in a multiple myeloma patient treated with an autologous bone marrow transplant. AmJ Hematol. 2003 Apr;72(4):274-7.

22. Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM,Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC,Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, RizzoJD, Schiller G, Schouten HC, Zhang MJ, Lymphoma Study Writing Committee, International BoneMarrow Transplant Registry and Autologous Blood and Marrow Transplant Registry. A comparison ofallogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003 Apr01;101(7):2476-82.

23. Lee SJ, Loberiza FR, Rizzo JD, Soiffer RJ, Antin JH, Weeks JC. Optimistic expectations and survival afterhematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003 Jun;9(6):389-96.

24. Rizzo JD, Williams S, Wu JT, Pecora AL, Lazarus HM, Bolwell B, Fields KK, Gale RP, Elfenbein G,Horowitz MM, Antman KH. Syngeneic hematopoietic stem cell transplantation for women withmetastatic breast cancer. Bone Marrow Transplant. 2003 Jul;32(2):151-5.

25. Serna DS, Lee SJ, Zhang MJ, Baker kS, Eapen M, Horowitz MM, Klein JP, Rizzo JD, Loberiza FR Jr.Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronicleukemia by ethnicity in the United States and Canada. J Clin Oncol. 2003 Oct 15;21(20):3754-60.

26. Bierman PJ, Sweetenham JW, Loberiza FR Jr, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van BesienK, Vose JM, Horowitz M, Goldstone A, Lymphoma Working Committee of the International BoneMarrow Transplant Registry and the European Group for Blood and Marrow Transplantation.Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison withallogeneic and autologous transplantation--The Lymphoma Working Committee of the InternationalBone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J

12 / 30

Clin Oncol. 2003 Oct 15;21(20):3744-53. 27. van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, Freytes CO, Gibson J,

Horowitz MM, Inwards DJ, Marks DI, Martino R, Maziarz RT, Molina A, Pavlovsky S, Pecora AL,Schouten HC, Shea TC, Lazarus HM, Rizzo JD, Vose JM. Comparison of autologous and allogeneichematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003 Nov 15;102(10):3521-9.

28. Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, Christiansen NP, Freytes CO, Gale RP,Gibson J, Giralt SA, Herzig RH, Lemaistre CF, McCarthy PL Jr, Nimer SD, Petersen FB, SchenkeinDP, Wiernik PH, Wiley JM, Loberiza FR, Lazarus HM, van Biesen K, Horowitz MM. Autologoustransplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.Biol Blood Marrow Transplant. 2004 Feb;10(2):116-27.

29. Loberiza FR, Zhang M, Rizzo JD, Lee SJ, Klein JP, Logan BR, Eapen M, Serna DS, Lemaistre CF,Horowitz MM. Patient and transplant center factors associated with 100D mortality after receivingallogeneic hematopoietic stem cell transplantation (HSCT). J Clin Oncol. 2004 Jul15;22(14_suppl):6026.

30. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP,Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A,Weisdorf DJ, Antin JH, Horowitz MM. A decision analysis of allogeneic bone marrow transplantationfor the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associatedwith improved outcome. Blood. 2004 Jul 15;104(2):579-85.

31. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, KlumppTR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, VoseJM, Lazarus HM, van Besien K, Lymphoma Working Committee of the International Bone MarrowTransplant Registry. Myeloablative allogeneic hematopoietic stem cell transplantation in patients whoexperience relapse after autologous stem cell transplantation for lymphoma: a report of theInternational Bone Marrow Transplant Registry. Blood. 2004 Dec 01;104(12):3797-803.

32. Rizzo JD. Evidence-based medicine: can it be applied to stimulation of erythropoiesis for patients withmalignancy? Best Pract Res Clin Haematol. 2005;18(3):439-48.

33. Andrykowski MA, Bishop MM, Hahn EA, Cella DF, Beaumont JL, Brady MJ, Horowitz MM, SobocinskiKA, Rizzo JD, Wingard JR. Long-term health-related quality of life, growth, and spiritual well-beingafter hematopoietic stem-cell transplantation. J Clin Oncol. 2005 Jan 20;23(3):599-608.

34. Loberiza FR Jr, Zhang MJ, Lee SJ, Klein JP, LeMaistre CF, Serna DS, Eapen M, Bredeson CN, HorowitzMM, Rizzo JD. Association of transplant center and physician factors on mortality after hematopoieticstem cell transplantation in the United States. Blood. 2005 Apr 01;105(7):2979-87.

35. Curtis RE, Metayer C, Rizzo JD, Socié G, Sobocinski KA, Flowers ME, Travis WD, Travis LB, HorowitzMM, Deeg HJ. Impact of chronic GVHD therapy on the development of squamous-cell cancers afterhematopoietic stem-cell transplantation: an international case-control study. Blood. 2005 May15;105(10):3802-11. PMCID: PMC1895092

36. Nanda A, Rizzo JD, Vogelsang GB. A case of retroperitoneal fibrosis in a patient following HSCT. BoneMarrow Transplant. 2005 Jun;35(11):1125-6.

37. Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, Bredeson CN, Horowitz MM.Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation forleukemia. Chest. 2005 Jul;128(1):153-61.

38. Jones R, Nieto Y, Rizzo JD, Wall D, Wingard JR, McCarthy P Jr, Hahn T, Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. The evolution of theevidence-based review: evaluating the science enhances the art of medicine--statement of the SteeringCommittee for Evidence-Based Reviews of the American Society for Blood and MarrowTransplantation. Biol Blood Marrow Transplant. 2005 Nov;11(11):819-22.

39. Schwake CJ, Eapen M, Lee SJ, Freytes CO, Giralt SA, Navarro WH, Rizzo JD, van Besien K, Loberiza FRJr. Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion ofracial or ethnic minorities. Biol Blood Marrow Transplant. 2005 Dec;11(12):988-98.

40. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D,Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D,McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M,Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria forclinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. BiolBlood Marrow Transplant. 2005 Dec;11(12):945-56.

41. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, Davies SM, Ferrara JL, Socié G.

13 / 30

Recommended screening and preventive practices for long-term survivors after hematopoietic celltransplantation: joint recommendations of the European Group for Blood and Marrow Transplantation,the Center for International Blood and Marrow Transplant Research, and the American Society ofBlood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006 Feb;12(2):138-51.

42. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, Davies SM, Ferrara JL, Socié G.Recommended screening and preventive practices for long-term survivors after hematopoietic celltransplantation: joint recommendations of the European Group for Blood and Marrow Transplantation,Center for International Blood and Marrow Transplant Research, and the American Society for Bloodand Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant. 2006Feb;37(3):249-61.

43. Navarro WH, Loberiza FR Jr, Bajorunaite R, van Besien K, Vose JM, Lazarus HM, Rizzo JD. Effect ofbody mass index on mortality of patients with lymphoma undergoing autologous hematopoietic celltransplantation. Biol Blood Marrow Transplant. 2006 May;12(5):541-51.

44. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, CourielD, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ, Design ofClinical Trials Working Group. National Institutes of Health Consensus Development Project onCriteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical TrialsWorking Group report. Biol Blood Marrow Transplant. 2006 May;12(5):491-505.

45. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, ChamplinRE, International Bone Marrow Transplant Registry, European Group for Blood and MarrowTransplantation. Long-term outcome of patients given transplants of mobilized blood or bone marrow:A report from the International Bone Marrow Transplant Registry and the European Group for Bloodand Marrow Transplantation. Blood. 2006 Dec 15;108(13):4288-90. PMCID: PMC1895450

46. Tomblyn MR, Rizzo JD. Are there circumstances in which phase 2 study results should be practice-changing? Hematology Am Soc Hematol Educ Program. 2007:489-92.

47. Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y, Sanders JE, Smith FO 3rd,Wilmot F, McCarthy PL Jr, Hahn T. The role of cytotoxic therapy with hematopoietic stem celltransplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. BiolBlood Marrow Transplant. 2007 Jan;13(1):1-25.

48. Bishop MM, Beaumont JL, Hahn EA, Cella D, Andrykowski MA, Brady MJ, Horowitz MM, SobocinskiKA, Rizzo JD, Wingard JR. Late effects of cancer and hematopoietic stem-cell transplantation onspouses or partners compared with survivors and survivor-matched controls. J Clin Oncol. 2007 Apr10;25(11):1403-11.

49. Lazarus HM, Stiff PJ, Carreras J, Logan BR, Akard L, Bolwell BJ, Childs RW, Gale RP, Klein JP, Lill MC,Pérez WS, Stadtmauer EA, Rizzo JD. Utility of single versus tandem autotransplants for advancedtestes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR)analysis. Biol Blood Marrow Transplant. 2007 Jul;13(7):778-89.

50. Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanouilides C, Nath R, Parker P, Porter D, SandmaierB, Waller EK, Barker J, Pavletic S, Weisdorf D. Reduced-intensity conditioning for unrelated donorprogenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrowdonor program. Biol Blood Marrow Transplant. 2007 Jul;13(7):844-52.

51. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B,Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE, American Society of ClinicalOncology, American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer:2007 American Society of Clinical Oncology/American Society of Hematology clinical practiceguideline update. J Clin Oncol. 2008 Jan 01;26(1):132-49.

52. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B,Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin inpatients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncologyclinical practice guideline update. Blood. 2008 Jan 01;111(1):25-41.

53. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D,Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM,Champlin RE, Stiff PJ, Niederwieser D. Allogeneic hematopoietic cell transplantation for metastaticbreast cancer. Bone Marrow Transplant. 2008 Mar;41(6):537-45.

54. Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, Brown C, Chaudhry MA,Horowitz MM, Kurian S, Quinlan D, Muehlenbien CE, Russell JA, Savoie L, Rizzo JD, Stewart DA.Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to

14 / 30

allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood MarrowTransplant. 2008 Sep;14(9):993-1003. PMCID: PMC3321981

55. Lazarus HM, Carreras J, Boudreau C, Loberiza FR Jr, Armitage JO, Bolwell BJ, Freytes CO, Gale RP,Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S,Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, SernaDS, Horowitz MM, Rizzo JD, Center For International Blood & Marrow Transplant Research(CIBMTR). Influence of age and histology on outcome in adult non-Hodgkin lymphoma patientsundergoing autologous hematopoietic cell transplantation (HCT): a report from the Center ForInternational Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant.2008 Dec;14(12):1323-33. PMCID: PMC2638759

56. Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME,Friedman DL, Horowitz MM, Wingard JR, Deeg HJ. Solid cancers after allogeneic hematopoietic celltransplantation. Blood. 2009 Jan 29;113(5):1175-83. PMCID: PMC2635083

57. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B. Reduced-intensityconditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by thecenter for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009Mar;15(3):367-9. PMCID: PMC3110087

58. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, Leitman SF, Anderlini P,Haagenson MD, Kurian S, Klein JP, Horowitz MM, Confer DL. Adverse events among 2408 unrelateddonors of peripheral blood stem cells: results of a prospective trial from the National Marrow DonorProgram. Blood. 2009 Apr 09;113(15):3604-11.

59. Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, KingmaDW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE. Risk factors for lymphoproliferativedisorders after allogeneic hematopoietic cell transplantation. Blood. 2009 May 14;113(20):4992-5001.

60. Jones RB, Nieto Y, Wall D, Wingard JR, Rizzo JD, McCarthy PL Jr, Oliansky D, Hahn T, ASBMT SteeringCommittee on Evidence-Based Reviews. Methodology for updating published evidence-based reviewsevaluating the role of blood and marrow transplantation in the treatment of selected diseases: a policystatement by the American Society for Blood and Marrow Transplantation. Biol Blood MarrowTransplant. 2009 Jun;15(6):761-2.

61. Loberiza FR Jr, Lee SJ, Freytes CO, Giralt SA, Van Besien K, Kurian S, del Cerro P, Toro JJ, Williams LA,Ketelsen SW, Navarro WH, Rizzo JD. Methodological and logistical considerations to study designand data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoieticcell transplantation. Biol Blood Marrow Transplant. 2009 Aug;15(8):903-9.

62. Marks DI, Ballen K, Logan BR, Wang Z, Sobocinski KA, Bacigalupo A, Burns LJ, Gupta V, Ho V,McCarthy PL, Ringdén O, Schouten HC, Seftel M, Rizzo JD. The effect of smoking on allogeneictransplant outcomes. Biol Blood Marrow Transplant. 2009 Oct;15(10):1277-87.

63. Majhail NS, Bajorunaite R, Lazarus HM, Wang Z, Klein JP, Zhang MJ, Rizzo JD. Long-term survival andlate relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol. 2009 Oct;147(1):129-39.

64. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB,Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R,Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, LazarusHM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem celltransplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009Nov;15(11):1455-64.

65. Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA,Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT,Workshop Participants. Improving cellular therapy for primary immune deficiency diseases:recognition, diagnosis, and management. J Allergy Clin Immunol. 2009 Dec;124(6):1152-60.e12.

66. Baker KS, Davies SM, Majhail NS, Hassebroek A, Klein JP, Ballen KK, Bigelow CL, Frangoul HA, HardyCL, Bredeson C, Dehn J, Friedman D, Hahn T, Hale G, Lazarus HM, LeMaistre CF, Loberiza F,Maharaj D, McCarthy P, Setterholm M, Spellman S, Trigg M, Maziarz RT, Switzer G, Lee SJ, RizzoJD. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic celltransplantation. Biol Blood Marrow Transplant. 2009 Dec;15(12):1543-54.

67. Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, AnasettiC, Maziarz RT. Impending challenges in the hematopoietic stem cell transplantation physicianworkforce. Biol Blood Marrow Transplant. 2009 Dec;15(12):1493-501.

15 / 30

68. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, SandmaierBM, Barrett J, Blaise D, Lowski R, Horowitz M. Defining the intensity of conditioning regimens:working definitions. Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33.

69. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO,Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL,Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, HariPN. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuselarge B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010Jan;16(1):35-45.

70. Somerfield MR, Rizzo JD. Can a modest exercise program really improve physical functioning and qualityof life among recipients of hematopoietic SCT? Bone Marrow Transplant. 2010 Feb;45(2):217-8.

71. Murphy EA, Ferguson SS, Omondi NA, Getzendaner LC, Gajewski JL, Goldstein GA, Wingard JR, RizzoJD, Majhail NS. The National Marrow Donor Program's symposium on patient advocacy in cellulartransplantation therapy: addressing barriers to hematopoietic cell transplantation. Biol Blood MarrowTransplant. 2010 Feb;16(2):147-56.

72. Bishop MM, Lee SJ, Beaumont JL, Andrykowski MA, Rizzo JD, Sobocinski KA, Wingard JR. Thepreventive health behaviors of long-term survivors of cancer and hematopoietic stem celltransplantation compared with matched controls. Biol Blood Marrow Transplant. 2010Feb;16(2):207-14.

73. Hari PN, Majhail NS, Zhang MJ, Hassebroek A, Siddiqui F, Ballen K, Bashey A, Bird J, Freytes CO, GibsonJ, Hale G, Holmberg L, Kamble R, Kyle RA, Lazarus HM, LeMaistre CF, Loberiza F, Maiolino A,McCarthy PL, Milone G, Omondi N, Reece DE, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P,Lee SJ, Rizzo JD, Mehta P. Race and outcomes of autologous hematopoietic cell transplantation formultiple myeloma. Biol Blood Marrow Transplant. 2010 Mar;16(3):395-402.

74. Loberiza FR Jr, Lee SJ, Klein JP, Hassebroek A, Dehn JG, Frangoul HA, Hahn T, Hale G, Lazarus HM,LeMaistre CF, Maziarz RT, Rizzo JD, Majhail NS. Outcomes of hematologic malignancies afterunrelated donor hematopoietic cell transplantation according to place of residence. Biol Blood MarrowTransplant. 2010 Mar;16(3):368-75.

75. Litzow MR, Tarima S, Pérez WS, Bolwell BJ, Cairo MS, Camitta BM, Cutler CS, de Lima M, Dipersio JF,Gale RP, Keating A, Lazarus HM, Luger S, Marks DI, Maziarz RT, McCarthy PL, Pasquini MC,Phillips GL, Rizzo JD, Sierra J, Tallman MS, Weisdorf DJ. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010 Mar 04;115(9):1850-7.

76. Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M, Horowitz MM, Rizzo JD. Relapseand late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantationfor chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010 Apr 10;28(11):1888-95.PMCID: PMC2860369

77. O'Donnell PV, Pedersen TL, Confer DL, Rizzo JD, Pulsipher MA, Stroncek D, Leitman S, Anderlini P,Donor Health and Safety Working Committee from Center for International Blood and MarrowTransplant Research (CIBMTR). Practice patterns for evaluation, consent, and care of related donorsand recipients at hematopoietic cell transplantation centers in the United States. Blood. 2010 Jun17;115(24):5097-101. PMCID: PMC2890146

78. Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, Majhail NS, Lee SJ, Horowitz MM.Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010 Jul15;116(14):3469-76. PMCID: PMC3153958

79. Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, Bredeson CN, Gupta V, Maziarz RT,Hale GA, Litzow MR, Logan B, Bornhauser M, Giller RH, Isola L, Marks DI, Rizzo JD, PasquiniMC. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol BloodMarrow Transplant. 2010 Aug;16(8):1099-106.

80. Majhail NS, Omondi NA, Denzen E, Murphy EA, Rizzo JD. Access to hematopoietic cell transplantation inthe United States. Biol Blood Marrow Transplant. 2010 Aug;16(8):1070-5.

81. Navarro WH, Agovi MA, Logan BR, Ballen K, Bolwell BJ, Frangoul H, Gupta V, Hahn T, Ho VT, JuckettM, Lazarus HM, Litzow MR, Liesveld JL, Moreb JS, Marks DI, McCarthy PL, Pasquini MC, RizzoJD. Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation(HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant. 2010Oct;16(10):1442-50.

82. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Somerfield MR, Temin S. American society of clinicaloncology/american society of hematology clinical practice guideline update on the use of epoetin and

16 / 30

darbepoetin in adult patients with cancer. J Oncol Pract. 2010 Nov;6(6):317-20. 83. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk

D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR, American Society of Hematology and theAmerican Society of Clinical Oncology Practice Guideline Update Committee. American Society ofHematology/American Society of Clinical Oncology clinical practice guideline update on the use ofepoetin and darbepoetin in adult patients with cancer. Blood. 2010 Nov 18;116(20):4045-59.

84. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, EvanchukD, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR, American Society of Clinical Oncology,American Society of Hematology. American Society of Clinical Oncology/American Society ofHematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patientswith cancer. J Clin Oncol. 2010 Nov 20;28(33):4996-5010.

85. Wingard JR, Huang IC, Sobocinski KA, Andrykowski MA, Cella D, Rizzo JD, Brady M, Horowitz MM,Bishop MM. Factors associated with self-reported physical and mental health after hematopoietic celltransplantation. Biol Blood Marrow Transplant. 2010 Dec;16(12):1682-92.

86. Uberti JP, Agovi MA, Tarima S, Haagenson M, Gandham S, Anasetti C, Baker KS, Bolwell BJ, BornhauserM, Chan KW, Copelan E, Davies SM, Finke J, Hale GA, Kollman C, McCarthy PL, RatanatharathornV, Ringdén O, Weisdorf DJ, Rizzo JD. Comparative analysis of BU and CY versus CY and TBI in fullintensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone MarrowTransplant. 2011 Jan;46(1):34-43.

87. Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM, Bolwell B, Wingard JR, SocieG. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011 Jan 06;117(1):316-22.

88. Turbeville S, Nicely H, Rizzo JD, Pedersen TL, Orchard PJ, Horwitz ME, Horwitz EM, Veys P, Bonfim C,Al-Seraihy A. Clinical outcomes following hematopoietic stem cell transplantation for the treatment ofmucopolysaccharidosis VI. Mol Genet Metab. 2011 Feb;102(2):111-5.

89. Loren AW, Chow E, Jacobsohn DA, Gilleece M, Halter J, Joshi S, Wang Z, Sobocinski KA, Gupta V, HaleGA, Marks DI, Stadtmauer EA, Apperley J, Cahn JY, Schouten HC, Lazarus HM, Savani BN,McCarthy PL, Jakubowski AA, Kamani NR, Hayes-Lattin B, Maziarz RT, Warwick AB, Sorror ML,Bolwell BJ, Socié G, Wingard JR, Rizzo JD, Majhail NS. Pregnancy after hematopoietic celltransplantation: a report from the late effects working committee of the Center for International Bloodand Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2011 Feb;17(2):157-66.PMCID: PMC3017731

90. Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, Bredeson CN, CarabasiMH, Gupta V, Hale GA, Khoury HJ, Juckett MB, Litzow MR, Martino R, McCarthy PL, Smith FO, Rizzo JD, Pasquini MC. Reducing the risk for transplantation-related mortality after allogeneichematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011 Mar01;29(7):805-13. PMCID: PMC3068057

91. Majhail NS, Bajorunaite R, Lazarus HM, Wang Z, Klein JP, Zhang MJ, Rizzo JD. High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first orsecond CR. Bone Marrow Transplant. 2011 Mar;46(3):385-92.

92. Barker CC, Agovi MA, Logan B, Lazarus HM, Ballen KK, Gupta V, Hale GA, Frangoul H, Ho V, Rizzo JD,Pasquini MC, Regimen-Related Toxicity Writing Committee, Center for International Blood andMarrow Transplant Research. Childhood obesity and outcomes after bone marrow transplantation forpatients with severe aplastic anemia. Biol Blood Marrow Transplant. 2011 May;17(5):737-44.

93. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM,Bolwell B, Rizzo JD, Socié G. Long-term survival and late deaths after allogeneic hematopoietic celltransplantation. J Clin Oncol. 2011 Jun 01;29(16):2230-9.

94. Majhail NS, Murphy EA, Omondi NA, Robinett P, Gajewski JL, LeMaistre CF, Confer D, Rizzo JD.Allogeneic transplant physician and center capacity in the United States. Biol Blood MarrowTransplant. 2011 Jul;17(7):956-61.

95. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S,Seber A, Socie G, Szer J, Lint MT, Wingard JR, Tichelli A. Recommended screening and preventivepractices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter.2012;34(2):109-33.

96. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S,Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A, Center for International Blood andMarrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation

17 / 30

(ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood andMarrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and NewZealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT),Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Recommended screening andpreventive practices for long-term survivors after hematopoietic cell transplantation. Hematol OncolStem Cell Ther. 2012;5(1):1-30.

97. Socié G, Rizzo JD. Second solid tumors: screening and management guidelines in long-term survivors afterallogeneic stem cell transplantation. Semin Hematol. 2012 Jan;49(1):4-9.

98. Jim HS, Syrjala KL, Rizzo D. Supportive care of hematopoietic cell transplant patients. Biol Blood MarrowTransplant. 2012 Jan;18(1 Suppl):S12-6.

99. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S,Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A, Center for International Blood andMarrow Transplant Research, American Society for Blood and Marrow Transplantation, EuropeanGroup for Blood and Marrow Transplantation, Asia-Pacific Blood and Marrow Transplantation Group,Bone Marrow Transplant Society of Australia and New Zealand, East Mediterranean Blood andMarrow Transplantation Group, Sociedade Brasileira de Transplante de Medula Ossea. Recommendedscreening and preventive practices for long-term survivors after hematopoietic cell transplantation.Bone Marrow Transplant. 2012 Mar;47(3):337-41.

100. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, OkamotoS, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A, Center for International Blood andMarrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation(ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood andMarrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and NewZealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT),,Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Recommended screening andpreventive practices for long-term survivors after hematopoietic cell transplantation. Biol BloodMarrow Transplant. 2012 Mar;18(3):348-71.

101. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donorversus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.Blood. 2012 Apr 26;119(17):3908-16.

102. Ballen KK, Klein JP, Pedersen TL, Bhatla D, Duerst R, Kurtzberg J, Lazarus HM, LeMaistre CF, McCarthyP, Mehta P, Palmer J, Setterholm M, Wingard JR, Joffe S, Parsons SK, Switzer GE, Lee SJ, Rizzo JD,Majhail NS. Relationship of race/ethnicity and survival after single umbilical cord bloodtransplantation for adults and children with leukemia and myelodysplastic syndromes. Biol BloodMarrow Transplant. 2012 Jun;18(6):903-12.

103. Majhail NS, Brazauskas R, Hassebroek A, Bredeson CN, Hahn T, Hale GA, Horowitz MM, Lazarus HM,Maziarz RT, Wood WA, Parsons SK, Joffe S, Rizzo JD, Lee SJ, Hayes-Lattin BM. Outcomes ofallogeneic hematopoietic cell transplantation for adolescent and young adults compared with childrenand older adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012 Jun;18(6):861-73.PMCID: PMC3288160

104. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN,Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First- and second-line systemic treatment ofacute graft-versus-host disease: recommendations of the American Society of Blood and MarrowTransplantation. Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63.

105. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease inducedgraft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensityconditioning. Biol Blood Marrow Transplant. 2012 Nov;18(11):1727-33.

106. Martinez C, Rizzo JD, Reeves D. Comprehensive stem cell transplant (SCT) outcome data submission. JClin Oncol. 2012 Dec;30(34_suppl):293.

107. Omondi NA, Ferguson SE, Majhail NS, Denzen EM, Buchanan GR, Haight AE, Labotka RJ, Rizzo JD,Murphy EA. Barriers to hematopoietic cell transplantation clinical trial participation of africanamerican and black youth with sickle cell disease and their parents. J Pediatr Hematol Oncol. 2013May;35(4):289-98.

108. Akpek G, Pasquini MC, Logan B, Agovi MA, Lazarus HM, Marks DI, Bornhaeüser M, Ringdén O,Maziarz RT, Gupta V, Popat U, Maharaj D, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthyPL, Ho VT. Effects of spleen status on early outcomes after hematopoietic cell transplantation. BoneMarrow Transplant. 2013 Jun;48(6):825-31.

18 / 30

109. Majhail NS, Rizzo JD, Hahn T, Lee SJ, McCarthy PL, Ammi M, Denzen E, Drexler R, Flesch S, James H,Omondi N, Pedersen TL, Murphy E, Pederson K. Pilot study of patient and caregiver out-of-pocketcosts of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013Jun;48(6):865-71.

110. Hahn T, McCarthy PL Jr, Hassebroek A, Bredeson C, Gajewski JL, Hale GA, Isola LM, Lazarus HM, LeeSJ, Lemaistre CF, Loberiza F, Maziarz RT, Rizzo JD, Joffe S, Parsons S, Majhail NS. Significantimprovement in survival after allogeneic hematopoietic cell transplantation during a period ofsignificantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013 Jul01;31(19):2437-49.

111. McCarthy PL Jr, Hahn T, Hassebroek A, Bredeson C, Gajewski J, Hale G, Isola L, Lazarus HM, Lee SJ,Lemaistre CF, Loberiza F, Maziarz RT, Rizzo JD, Joffe S, Parsons S, Majhail NS. Trends in use ofand survival after autologous hematopoietic cell transplantation in North America, 1995-2005:significant improvement in survival for lymphoma and myeloma during a period of increasingrecipient age. Biol Blood Marrow Transplant. 2013 Jul;19(7):1116-23.

112. Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, PalmerJ, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR. Divergent effects of novelimmunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome afterautologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood MarrowTransplant. 2013 Sep;19(9):1368-73.

113. Majhail NS, Rizzo JD. Surviving the cure: long term followup of hematopoietic cell transplant recipients.Bone Marrow Transplant. 2013 Sep;48(9):1145-51.

114. Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME,Horowitz MM. Impact of donor source on hematopoietic cell transplantation outcomes for patientswith myelodysplastic syndromes (MDS). Blood. 2013 Sep 12;122(11):1974-82.

115. Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR,Laport GG, Zhu X, McCarthy PL, Ho VT, Cooke KR, Armstrong E, Smith A, Rizzo JD, Burkart JM,Pasquini MC. Prospective cohort study comparing intravenous busulfan to total body irradiation inhematopoietic cell transplantation. Blood. 2013 Dec 05;122(24):3871-8.

116. Pollack J, Schaper K, Renner R, Martinez C, Sorenson S, et al. Extending the Bridg Model withHematopoietic Cell Transplant Concepts. Biology of blood and marrow transplantation: journal of theAmerican Society for Blood and Marrow Transplantation. 2014;20(2 Supplement): S207-208.

117. Joshi S, Savani BN, Chow EJ, Gilleece MH, Halter J, Jacobsohn DA, Pidala J, Quinn GP, Cahn JY,Jakubowski AA, Kamani NR, Lazarus HM, Rizzo JD, Schouten HC, Socie G, Stratton P, Sorror ML,Warwick AB, Wingard JR, Loren AW, Majhail NS. Clinical guide to fertility preservation inhematopoietic cell transplant recipients. Bone Marrow Transplant. 2014 Apr;49(4):477-84.

118. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, OkamotoS, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A, Center for International Blood andMarrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation(ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood andMarrow Transplantation Group (APBMT), Bone Marrow Transplantation Society of Australia andNew Zeland (BMTSANZ), East Mediterrnean Blood and Marrow Transplantation Group (EMBMT),Sociedale Brasileira de Transplante de Medula Ossea (SBTMO). [Recommended screening andpreventive practices for long-term survivors after hematopoietic cell transplantation]. Rinsho Ketsueki.2014 Jun;55(6):607-32.

119. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ,Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W. Validation and refinement of the Disease Risk Indexfor allogeneic stem cell transplantation. Blood. 2014 Jun 05;123(23):3664-71.

120. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M,Confer D, Maiers M. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. NEngl J Med. 2014 Jul 24;371(4):339-48. PMCID: PMC5965695

121. Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC, Passweg J, Chaudhri N,Ghavamzadeh A, Solh HE, Atsuta Y, Szer J, Kodera Y, Niederweiser D, Gratwohl A, Horowitz MM.Challenges and opportunities for HSCT outcome registries: perspective from international HSCTregistries experts. Bone Marrow Transplant. 2014 Aug;49(8):1016-21.

122. Jacobsen PB, Le-Rademacher J, Jim H, Syrjala K, Wingard JR, Logan B, Wu J, Majhail NS, Wood W, Rizzo JD, Geller NL, Kitko C, Faber E, Abidi MH, Slater S, Horowitz MM, Lee SJ. Exercise andstress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant

19 / 30

Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant. 2014 Oct;20(10):1530-6. 123. Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski

W, Rizzo JD, Hari PN, Hamadani M. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol BloodMarrow Transplant. 2014 Dec;20(12):1926-31.

124. Knight JM, Szabo A, Zhao S, Lyness JM, Sahler OJ, Liesveld JL, Sander T, Rizzo JD, Hillard CJ,Moynihan JA. Circulating endocannabinoids during hematopoietic stem cell transplantation: A pilotstudy. Neurobiol Stress. 2015;2:44-50. PMCID: PMC4476410

125. Renner R, Carlis J, Maiers M, Rizzo JD, O'Neil C, et al. Integration of Hematopoietic Cell TransplantationOutcomes Data.Data integration in the life sciences:...International Workshop,DILS...: proceedings.DILS (Conference). 2015, :139-146.

126. Kenzik K, Huang IC, Rizzo JD, Shenkman E, Wingard J. Relationships among symptoms, psychosocialfactors, and health-related quality of life in hematopoietic stem cell transplant survivors. Support CareCancer. 2015 Mar;23(3):797-807.

127. Ballen KK, Logan BR, Laughlin MJ, He W, Ambruso DR, Armitage SE, Beddard RL, Bhatla D, HwangWY, Kiss JE, Koegler G, Kurtzberg J, Nagler A, Oh D, Petz LD, Price TH, Quinones RR,Ratanatharathorn V, Rizzo JD, Sazama K, Scaradavou A, Schuster MW, Sender LS, Shpall EJ,Spellman SR, Sutton M, Weitekamp LA, Wingard JR, Eapen M. Effect of cord blood processing ontransplantation outcomes after single myeloablative umbilical cord blood transplantation. Biol BloodMarrow Transplant. 2015 Apr;21(4):688-95. PMCID: PMC4359657

128. Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD,Saber W, Hari PN. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibilityof later transplantation. Bone Marrow Transplant. 2015 Jul;50(7):914-7.

129. Majhail NS, Mau LW, Chitphakdithai P, Payton T, Eckrich M, Joffe S, Lee SJ, LeMaistre CF,LeRademacher J, Loberiza F, Logan B, Parsons SK, Repaczki-Jones R, Robinett P, Rizzo JD, MurphyE, Denzen EM. National Survey of Hematopoietic Cell Transplantation Center Personnel,Infrastructure, and Models of Care Delivery. Biol Blood Marrow Transplant. 2015 Jul;21(7):1308-14.PMCID: PMC4466059

130. Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, RizzoDJ, Saber W, Hari P, Fenske TS. Safety of outpatient autologous hematopoietic cell transplantation formultiple myeloma and lymphoma. Bone Marrow Transplant. 2015 Jul;50(7):947-53. PMCID:PMC4490016

131. Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC.Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation ComorbidityIndex: A Center for International Blood and Marrow Transplant Research Study. Biol Blood MarrowTransplant. 2015 Aug;21(8):1479-87. PMCID: PMC4512746

132. Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, Shaw BE. Survival of patients who develop solid tumorsfollowing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016 Jan;51(1):83-8.PMCID: PMC4570237

133. Knight JM, Rizzo JD, Logan BR, Wang T, Arevalo JM, Ma J, Cole SW. Low Socioeconomic Status,Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell TransplantRecipients. Clin Cancer Res. 2016 Jan 01;22(1):69-78. PMCID: PMC4703514

134. Majhail NS, Baker KS, Abetti B, Jahagirdar BN, Kamani N, Rizzo JD, Saber W, Salazar L, Schatz B,Syrjala KL, Wingard JR, Denzen EM. Patient and provider preferences: Treatment summary andsurvivorship care plans after hematopoietic cell transplant. J Clin Oncol. 2016 Jan 20;34(3_suppl):63.

135. Wood WA, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, Abidi MH, Wingard JR,Majhail NS, Geller NL, Rizzo JD, Fei M, Wu J, Horowitz MM, Lee SJ. Patient-reported physicalfunctioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer. 2016Jan 01;122(1):91-8. PMCID: PMC4707096

136. Shaw BE, Lee SJ, Horowitz MM, Wood WA, Rizzo JD, Flynn KE. Can we agree on patient-reportedoutcome measures for assessing hematopoietic cell transplantation patients? A study from theCIBMTR and BMT CTN. Bone Marrow Transplant. 2016 Sep;51(9):1173-9.

137. Denzen EM, Thao V, Hahn T, Lee SJ, McCarthy PL, Rizzo JD, Ammi M, Drexler R, Flesch S, James H,Omondi N, Murphy E, Pederson K, Majhail NS. Financial impact of allogeneic hematopoietic celltransplantation on patients and families over 2 years: results from a multicenter pilot study. BoneMarrow Transplant. 2016 Sep;51(9):1233-40. PMCID: PMC5014617

138. Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood

20 / 30

WA, Jim HSL, Wingard JR, Horowitz MM, Abidi MH, Fei M, Rawls L, Rizzo JD. Patient-ReportedOutcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic StemCell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902Trial. Biol Blood Marrow Transplant. 2016 12;22(12):2256-2263. PMCID: PMC5116244

139. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W,Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on theincidence and severity of post-transplantation viral infections. Bone Marrow Transplant. 201612;51(12):1602-1604.

140. Wingard JR, Wood WA, Martens M, Le-Rademacher J, Logan B, Knight JM, Jacobsen PB, Jim H, MajhailNS, Syrjala K, Rizzo JD, Lee SJ. Pretransplantation Exercise and Hematopoietic Cell TransplantationSurvival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN0902). Biol Blood Marrow Transplant. 2017 01;23(1):161-164. PMCID: PMC5182134

141. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S,Bartz K, Raj RV, Hari PN, Hamadani M. Salvage haploidentical hematopoietic cell transplantation forgraft rejection following a prior haploidentical allograft. Bone Marrow Transplant. 201701;52(1):147-150.

142. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W,Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P,Craig M, Horowitz MM, Hamadani M. Recipient Immune Modulation with Atorvastatin for AcuteGraft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood MarrowTransplant. 2017 Aug;23(8):1295-1302.

143. Hashmi SK, Bredeson C, Duarte RF, Farnia S, Ferrey S, Fitzhugh C, Flowers MED, Gajewski J, GastineauD, Greenwald M, Jagasia M, Martin P, Rizzo JD, Schmit-Pokorny K, Majhail NS. National Institutesof Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery WorkingGroup Report. Biol Blood Marrow Transplant. 2017 May;23(5):717-725. PMCID: PMC5378687

144. Arber DA, Borowitz MJ, Cessna M, Etzell J, Foucar K, Hasserjian RP, Rizzo JD, Theil K, Wang SA,Smith AT, Rumble RB, Thomas NE, Vardiman JW. Initial Diagnostic Workup of Acute Leukemia:Guideline From the College of American Pathologists and the American Society of Hematology. ArchPathol Lab Med. 2017 Oct;141(10):1342-1393.

145. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S,Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acutegastrointestinal graft-versus-host disease. Am J Hematol. 2017 Oct;92(10):E610-E611.

146. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N,Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for theTreatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017Nov;23(11):1955-1960.

147. Shaw, B. E., Brazauskas, R., Millard, H. R., Fonstad, R., Flynn, K. E., Abernethy, A., Vogel, J., Petroske,C., Mattila, D., Drexler, R., Lee, S. J., Horowitz, M. M. and Rizzo, J. D. (2017), Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. Cancer.doi:10.1002/cncr.30936

148. Shaw BE, Brazauskas R, Millard HR, Fonstad R, Flynn KE, Abernethy A, Vogel J, Petroske C, Mattila D,Drexler R, Lee SJ, Horowitz MM, Rizzo JD. Centralized patient-reported outcome data collection intransplantation is feasible and clinically meaningful. Cancer. 2017 Dec 01;123(23):4687-4700.PMCID: PMC5693638

149. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A,Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B,Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acutegraft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract disease. Haematologica.2018 04;103(4):717-727. PMCID: PMC5865423

150. D'Souza A, Millard H, Knight J, Brazauskas R, Lee SJ, Flynn KE, Rizzo JD, Shaw BE. Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation. Bone MarrowTransplant. 2018 08;53(8):1079-1082. PMCID: PMC6098949

151. Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D,Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M,Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J,DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA. ASBMT Practice GuidelinesCommittee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.

21 / 30

Biol Blood Marrow Transplant. 2018 06;24(6):1119-1124. 152. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD,

Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. PeripheralBlood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity ofCytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 08;24(8):1664-1670.

153. Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR,Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD. Repurposingexisting medications as cancer therapy: design and feasibility of a randomized pilot investigatingpropranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer. 2018May 24;18(1):593. PMCID: PMC5968588

154. Bhatt NS, Brazauskas R, Tecca HR, Vogel J, Mattila D, Lee SJ, Horowitz MM, Rizzo JD, Shaw BE.Female Sex is Associated With Poor Health-related Quality of Life in Children at 12 Months Post-Hematopoietic Cell Transplantation. J Pediatr Hematol Oncol. 2019 04;41(3):233-237. PMCID:PMC6301126

155. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN,Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A,Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ,Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI,Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H,Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, MahindraA, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, LitzowMR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome afterautotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018 11;74:130-136. PMCID:PMC6219911

156. Denzen EM, Preussler JM, Murphy EA, Baker KS, Burns LJ, Foster J, Idossa L, Moore HK, Payton TJ,Haven D, Jahagirdar B, Kamani N, Rizzo JD, Salazar L, Schatz BA, Syrjala KL, Wingard JR, MajhailNS. Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients ofHematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 03;25(3):562-569. PMCID:PMC6445667

157. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF,Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS,Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, HahnTE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM,Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirkJP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB,Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ,Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE. Related peripheral bloodstem cell donors experience more severe symptoms and less complete recovery at one year comparedto unrelated donors. Haematologica. 2019 04;104(4):844-854. PMCID: PMC6442962

158. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF,Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED,Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, HaightAE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK,Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, Horowitz MM, ConferDL, Shaw BE, Switzer GE. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-OldFemales after Marrow Donation: RDSafe Peds Results. Biol Blood Marrow Transplant. 201905;25(5):955-964. PMCID: PMC6511296

159. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B,D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M.Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell TransplantationPerformed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 201904;25(4):827-833.

160. Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF,Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP,Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, DuckworthK, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA,Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman

22 / 30

M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR,Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK,Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL. Effect ofAging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience:Report from the Related Donor Safety Study. Biol Blood Marrow Transplant. 2019 04;25(4):699-711.PMCID: PMC6453753

161. Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de ElviraCR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, PasswegJ, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T,Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S,Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A,Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de WreedeLC, van Zwet E, Putter H. Benchmarking of survival outcomes following haematopoietic stem celltransplantation: A review of existing processes and the introduction of an international system from theEuropean Society for Blood and Marrow Transplantation (EBMT) and the Joint AccreditationCommittee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2020 04;55(4):681-694. PMCID:PMC7113189

162. Renner R, Carlis J, Maiers M, Rizzo JD, O’Neill C, Horowitz M, Gee K, Confer D. Integration ofhematopoietic cell transplantation outcomes data : Data standards are not enough Lecture Notes inComputer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes inBioinformatics). 2015;9162:139-146.

163. Majhail NS, Rizzo JD. Screening and Prevention Guidelines for Hematopoietic Cell Transplant SurvivorsBlood and Marrow Transplantation Long Term Management: Prevention and Complications. 9September 2013:55-64.

164. Rizzo JD, Curtis RE, Deeg HJ, Travis LB. Response: Solid cancers after allogeneic hematopoietic celltransplantation Blood. 2009;114(1):225-226.

165. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B,Goode MJ, Jakubowski AA, Miller CB, Rarick MU, Regan DH, Lichtin AE. In reply Journal ofClinical Oncology. 2008;26(18):3098-3100.

166. Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J,Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD. Comparison ofPatient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage WithEvidence Development Study. JAMA Oncol. 2020 04 01;6(4):486-493. PMCID: PMC6990739

167. Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de ElviraCR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, PasswegJ, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T,Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S,Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A,Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de WreedeLC, van Zwet E, Putter H. Correction: Benchmarking of survival outcomes following haematopoieticstem cell transplantation: A review of existing processes and the introduction of an internationalsystem from the European Society for Blood and Marrow Transplantation (EBMT) and the JointAccreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2020Apr;55(4):838-839. PMCID: PMC7609270

168. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S,Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW. Propranolol inhibits molecular risk markers inHCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 0211;4(3):467-476. PMCID: PMC7013267

169. Knight JM, Rizzo JD, Wang T, He N, Logan BR, Spellman SR, Lee SJ, Verneris MR, Arevalo JMG, ColeSW. Molecular Correlates of Socioeconomic Status and Clinical Outcomes Following HematopoieticCell Transplantation for Leukemia. JNCI Cancer Spectr. 2019 Dec;3(4):pkz073. PMCID:PMC6859844

170. Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM,Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ,Horowitz MM. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe AplasticAnemia. Biol Blood Marrow Transplant. 2020 07;26(7):e161-e166. PMCID: PMC7206419

171. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P,

23 / 30

Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, SteinertP, Weisdorf DJ, Horowitz MM. Current Use of and Trends in Hematopoietic Cell Transplantation inthe United States. Biol Blood Marrow Transplant. 2020 08;26(8):e177-e182. PMCID: PMC7404814

172. Hong S, Brazauskas R, Hebert KM, Ganguly S, Abdel-Azim H, Diaz MA, Beattie S, Ciurea SO, SzwajcerD, Badawy SM, Gratwohl AA, LeMaistre C, Aljurf MDSM, Olsson RF, Bhatt NS, Farhadfar N, YaredJA, Yoshimi A, Seo S, Gergis U, Beitinjaneh AM, Sharma A, Lazarus H, Law J, Ulrickson M, HashemH, Schoemans H, Cerny J, Rizzieri D, Savani BN, Kamble RT, Shaw BE, Khera N, Wood WA,Hashmi S, Hahn T, Lee SJ, Rizzo JD, Majhail NS, Saber W. Community health status and outcomesafter allogeneic hematopoietic cell transplantation in the United States. Cancer. 2021 0215;127(4):609-618. PMCID: PMC7855526

173. Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, PasquiniM, Coe CL, Irwin MR, Raison CL, Drobyski WR. The IL-6 antagonist tocilizumab is associated withworse depression and related symptoms in the medically ill. Transl Psychiatry. 2021 01 18;11(1):58.PMCID: PMC7812704

174. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A,Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE,Horowitz MM, Hari PN, Hamadani M. Corrigendum to ‘Ixazomib for chronic Graft-Versus-HostDisease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood andMarrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation(2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005)) Transplantation andCellular Therapy. 2021.

175. Wingard JR, Ahn KW, Dandoy C, Perales MA, Wood WA, Logan B, Riches M, Rizzo JD. COVID-19 andHematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impactof the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for InternationalBlood and Marrow Transplantation Research Center Outcomes Forum. Transplant Cell Ther. 202107;27(7):533-539. PMCID: PMC8061634

176. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P,Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, SteinertP, Weisdorf DJ, Horowitz MM. Corrigendum to ‘Current Use and Trends in Hematopoietic CellTransplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182](Transplantation and Cellular Therapy (2020) 26/8(e177-e182) (S1083879120302251),(10.1016/j.bbmt.2020.04.013)) Transplantation and Cellular Therapy. 2021.

177. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A,Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN,Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host DiseaseProphylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant.2020 10;26(10):1876-1885. PMCID: PMC7571859

178. Majhail NS, Mau LW, Chitphakdithai P, Denzen EM, Joffe S, Lee SJ, LeMaistre CF, Loberiza F, ParsonsSK, Repaczki-Jones R, Robinett P, Douglas Rizzo J, Murphy E, Logan B, Le-Rademacher J.Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation inadults. Bone Marrow Transplant. 2020 05;55(5):906-917. PMCID: PMC7202970

179. Lazarus HM, Pérez WS, Klein JP, Kollman C, Bate-Boyle B, Bredeson CN, Gale RP, Geller RB, KeatingA, Litzow MR, Marks DI, Miller CB, Douglas Rizzo J, Spitzer TR, Weisdorf DJ, Zhang MJ, HorowitzMM. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloidleukaemia: a retrospective analysis from the Center for International Blood and Marrow TransplantResearch. Br J Haematol. 2006 Mar;132(6):755-69.

180. Elizabeth A Murphy , Navneet S. Majhail , Kevin Scott Baker , Beatrice Abetti , Balkrishna N. Jahagirdar ,Naynesh KamaniJ. Douglas Rizzo , Wael Saber , Lizette Salazar , Barry Schatz , Karen Leslie Syrjala, John R. Wingard , Ellen M Denzen. Patient and provider preferences: Treatment summary andsurvivorship care plans after hematopoietic cell transplant. Journal of Clinical Oncology. DOI:10.1200/jco.2016.34.3_suppl.63 Journal of Clinical Oncology 34, no. 3_suppl (January 20, 2016)63-63..

Editorials, Letters to Editor, Other1. Rizzo JD, Strom BF, Berlin J: Central vascular catheters and infection rates. N Engl J Med 328:445, 19932. Rizzo JD: Review of Handbook of Supportive Care in Cancer, Klastersky, Schimpff and Senn, eds. J Natl

Cancer Inst 87:1328, 1995

24 / 30

3. Rizzo JD, Cella D, Seidenfeld J: In reply: Letter to the Editor. J Clin Oncol 21:2224-2225.4. Rizzo JD: Clinical Bone Marrow and Blood Stem Cell Transplantation. [Book Review.] Bone Marrow

Transplant 35:319, 2005.5. Nanda A, Rizzo JD, Vogelsang GB: A Case of Retroperitoneal Fibrosis in a Patient following HSCT. [Letter]

Bone Marrow Transplant 35:1125-1126, 2005.6. Majhail NS, Rizzo JD. Late complications. In: Handbook of hematopoietic stem-cell transplantation;

(Wingard J, Gastineau DA, Leather HL, Snyder E, Szczepiorkowski ZM, eds), AABB, MA, USA.[Chapter] In press 2008

7. Majhail NS, Rizzo JD. Screening and prevention guidelines for hematopoietic cell transplant survivors. In:Hematopoietic Stem-Cell Transplantation: A Handbook for Clinicians, 2nd Edition; (Wingard J,Gastineau DA, Leather HL, Snyder E, Szczepiorkowski ZM, eds), AABB, MD, USA. [Chapter 8]2015 29

Abstracts1. SundarRaj N, RIZZO JD, Anderson S, Goodman W, Thoft R: Expression of unique cytoskeletal-associated

proteins upon activation stromal keratocytes during healing of radial keratotomy wounds. ARVO May,1988

2. RIZZO JD, Vogelsang V, Krumm S, Mock V, Frink B, Bass E: Outpatient BMT for hematologicmalignancies: cost-saving or cost-shifting? Blood 90:417a, 1997

3. RIZZO JD, Stiff P, Elias A: Autologous stem cell transplantation for small cell lung cancer. Proceedings ofAmerican Society Clinical Oncology 18:469a, 1999

4. Drobyski WR, Klein JP, Pietryga D, Flomenberg N, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor C, Horowitz MM, Juckett M, RIZZO JD, Bauer D, Burns WH, Casper JT: A comparativeanalysis of transplant outcomes in patients receiving unrelated versus highly HLA-disparatehaploidentical family member donor marrow grafts for the treatment of leukemia. Blood 94:564a, 1999

5. Vose J, RIZZO JD, Wu J, van Besien K, Lazarus H: Autotransplantation for non-hodgkin lymphoma in 1strelapse or 2nd complete remission - prognostic factor analysis. Blood 96:481a, 2000

6. RIZZO JD, Curtis R, Deeg H, Socié G, Travis L, Flowers M, Sobocinski K, Horowitz MM: Solid cancers insurvivors of allogeneic bone marrow transplantation (BMT). Blood 96:557a, 2000

7. RIZZO JD, Ostrowsky B, Horowitz MM, Jarvis W, Pearson M: Infection control and vaccination practices atU.S. and Canadian blood and marrow transplant centers. Program/Proceedings of the AmericanSociety of Clinical Oncology 20:20a, 2001

8. Williams SF, RIZZO JD, Wu J, Antman K, Horowitz MM: Syngeneic stem cell transplantation in metastaticbreast cancer. Biol Blood Marrow Transplant 7:98a, 2001

9. Metayer C, Curtis RE, Sobocinski KA, Horowitz MM, Vose JM, Weisdorf D, Bhatia S, Fay JW, Freytes CO,Goldstein SC, Herzig R, Keating A, Miller C, Nevill TJ, Pecora AL, RIZZO JD, Travis LB, WilliamsSF: Myelodysplastic syndrome (MDS) and leukemia after autotransplantation for lymphoma: amulticenter case-control study. Program/Proceedings of the American Society of Clinical Oncology20:7a, 2001

10. Lee SJ, Bishop MM, Odom LC, Hahn EA, Sobocinski KA, RIZZO JD, Brady MJ, Andrykowski M, Socie G,Cella D, Horowitz MM, Wingard JR, the Late Effects Working Committee of the IBMTR/ABMTR:Preventive health behaviors of stem cell transplant survivors. Blood 98:403a, 2001

11. Loberiza FR, Jr, RIZZO JD, Bredeson CN, Antin JH, Horowitz MM, Weeks JC, Lee SJ: Depressivesyndrome and early deaths following stem cell transplantation for hematologic diseases. Blood98:742a, 2001

12. Schmitz N, Champlin RE, Loberiza FR, Jr, Klein JP, RIZZO JD, Gratwohl A, Horowitz MM, theHistocompatibility and Stem Cell Sources Working Committee of the IBMTR: Long term follow-up ofallogeneic blood stem cell and bone marrow transplantation: a collaborative study of EBMT andIBMTR. Blood 98:744a, 2001

13. Serna DS, Zhang MJ, Scott-Baker K, Eapen M, Horowitz MM, Klein JP, Lee SJ, RIZZO JD, Loberiza Jr.FR: Trends in survival rates by race after allogeneic hematopoietic stem cell transplantation forleukemia in the United States and Canada. Blood 100:186a, 2002

14. Navarro WH, Loberiza FR, Bajorunaite R, Lazarus HM, RIZZO JD, van Besien K, Vose JM, Horowitz MMon behalf of the Lymphoma Working Committee of the Autologous Blood and Marrow TransplantRegistry (ABMTR). Impact of weight on mortality of patients with lymphoma undergoing autologoushematopoietic cell transplantation (AHCT). Meeting Proceedings of the American Society of ClinicalOncology 22:832a, 2003.

25 / 30

15. Ueno NT, RIZZO JD, Niederwieser D, Cheng Y, Antman K, Stiff PJ, Demirer T, Horowitz MM for the SolidTumor Working Committees of the International Bone Marrow Transplant Registry/The EuropeanGroup for Blood and Marrow Transplantation (IBMTR/EBMT). Review of allogeneic hematopoieticstem cell transplantation (ALLO HSCT) in metastatic breast cancer (MBC). Meeting Proceedings ofthe American Society of Clinical Oncology 22:832a, 2003

16. Bishop M.M., Hahn E., Cella D., Brady M.J., Andrykowski M.A., Beaumont J, RIZZO JD, Wingard JR. TheGift of Life Comes with a Price: The Impact of Hematopoietic Stem Cell Transplant on the Long-termQuality of Life of Survivors and their Spouses. Paper presented at the Annual BMT Tandem Meetingof the IBMTR/ABMTR and ASBMT, Orlando, FL. Biol Blood Marrow Transplant 10:S7, 2004

17. Bishop M.M., Hahn E., Cella D., Brady M.J., Andrykowski M.A., Beaumont J., RIZZO JD, Wingard J.R.The Gift of Life Comes with a Price: The Impact of Hematopoietic Stem Cell Transplant on the Long-term Quality of Life of Survivors and their Spouses. Psychooncology 13:S62-63, 2004

18. Champlin RE, Loberiza, Jr. FR, Eapen M, RIZZO JD, Bredeson CN, Wagner JE, Horowitz MM on behalf ofthe Histocompatibility Alternative Stem Cell Sources Working Committee of the Center forInternational Blood and Marrow Transplant Research (CIBMTR). Prevalence of microbiallycontaminated hematopoietic stem cell products. Blood 104:612a, 2004.

19. Andrykowski MA, Bishop MM, Hahn EA, Cella DF, Beaumont JL, Brady MJ, Horowitz, MM, Sobocinski,KA, RIZZO JD, Wingard JR. Long-term health-related quality of life (HRQOL), growth and spiritualwell-being after hematopoietic stem cell transplantation (HSCT). Presented at the 2nd AnnualConference of the American Psychosocial Oncology Society (APOS), Phoenix, AZ, January, 2005.Psycho-Oncology 14(Supp 1) S21, 2005.

20. Goldman JM, Sobocinski KA, Zhang MJ, Klein JP, Ketelsen SW, Giralt SA, Horowitz, MM, RIZZO JD, forthe Chronic Leukemia Working Committee of the Center for International Blood and MarrowTransplant Research. Long term outcome after allogeneic hematopoietic cell transplantation (HCT) forCML. Biol Blood Marrow Transplant 12:17, 2006.

21. Ueno NT, RIZZO JD, Cheng YC, Childs R, Stiff PJ, Demirer T, Horowitz M.M, Niederwieser D. Allogeneichematopoietic cell transplantation (allo HCT) for metastatic breast cancer (MBC). Biol Blood MarrowTransplant 12:32, 2006.

22. Graham HJ, Wade JC, RIZZO JD, Hari P, Miels S, Gruling RJ, Sorensen SH. Recognizing indications forphotopheresis in acute and chronic graft-versus-host disease patients. Biol Blood Marrow Transplant12:167, 2006.

23. Hayes-Lattin B, Carreras J, Zhang M-J, van Besien K, Vose JM, Lazarus HM, RIZZO JD, Hari P. Superiorsurvival after autologous vs. allogeneic hematopoietic stem cell transplantation (HCT) for diffuse largeB-cell lymphoma (DLBCL) not explained by differences in chemosensitivity. Blood 108:857a, 2006.

24. Joshua TV, RIZZO JD, Zhang M-J, Horowitz MM. Access to hematopoietic stem cell transplantation: effectof race and gender. Biol Blood Marrow Transplant 13:22, 2007.

25. Bishop MM, Beaumont JL, Lee SJ, Andrykowski MA, RIZZO JD, Wingard JR. Preventive health behaviorsof long-term hematopoietic cell transplant survivors. Biol Blood Marrow Transplant 13:48, 2007.

26. Fenske TS, Hari P, Carreras J, Zhang M-J, Kamble R, RIZZO JD, van Besien K, Lazarus HM, Vose JM onbehalf of the Writing Committee. Pre-transplant Rituximab therapy is associated with improvedprogression-free and overall survival in patients undergoing autologous hematopoietic stem celltransplantation for diffuse large B-cell lymphoma (DLBCL). Blood 110:116, 2007.

27. Baker KS, Hassebroek A, Ballen K, Bigelow C, Frangoul H, Hardy C, Lee S, Switzer G, RIZZO JD, KleinJP, Majhail N, Davies S. Impact of ethnicity and socioeconomic status on outcome of unrelated donor(URD) Hematopoietic Cell Transplantation (HcT)Blood 110:315, 2007.

28. Navarro WH, Agovi M-A, Logan B, Bacigalupo A, Ballen K, Bolwell B, Frangoul H, Gupta V, Hahn T,Juckett M, Lazarus HM, Litzow M, Liesveld J, Moreb J, Marks D, McCarthy P, RIZZO JD, on behalfof the CIBMTR writing committee. Obesity does not preclude safe and effective myeloablativehematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) in adults. Blood 112:26,2008.

29. Schriber JR, Agovi M-A, Ballen KK, Bacigalupo A, Hale GA, Gupta V, Lazarus HM, Litzow MR, MarksDI, Giller RH, Maziarz RT, Bornhauser M, Isola LM, Bredeson C, RIZZO JD. Second unrelated donor(URD) transplant as a rescue strategy for 122 patients with primary non-engraftment: results from theCIBMTR. Blood 112:295, 2008.

30. Majhail NS, Wang Z, Zhang M-J, Lazarus HM, Bajorunaite R, RIZZO JD. Long-term survival and laterelapse in 2-year survivors of autologous hematopoietic cell transplantation for lymphoma. Biol BloodMarrow Transplant 15:22-23, 2009.

26 / 30

31. O'Donnell P, Pedersen T, Confer D, Pulsipher M, RIZZO JD, Stroncek D, Leitman S, Anderlini P. Practicepatterns for evaluation, consent and care of related donors and recipients at hematopoietic stem celltransplant centers in the United States: is conflict-of-interest an unrecognized issue? Biol BloodMarrow Transplant 15:8-9, 2009.

32. Barker CC, Agovi M-A, Logan B, Gupta V, Lazarus HM, Ballen KK, Hale GA, Frangoul H, RIZZO JD,Pasquini MC. Obesity adversely affects survival of pediatric patients with severe aplastic anemia afterhematopoietic cell transplantation. Blood 114:271, 2009.

33. Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M, Horowitz MM, RIZZO JD. Long-term survival and late relapse in 5-year survivors of allogeneic hematopoietic-cell transplantation(HCT) for chronic myeloid leukemia (CML) in first chronic phase. Blood 114:1288, 2009.

34. Horan, J Logan BR, Agovi M-A, Lazarus HM, Bacigalupo A, Ballen K, Martino R, Juckett MB, Khoury HJ,Bredeson C, Gupta V, Smith FO, Hale G, Carabasi M, McCarthy PL, RIZZO JD, Pasquini MC.Reducing the risk for transplant related mortality after allogeneic hematopoietic cell transplantation:how much progress has been made? Blood 114:269, 2009.

35. Wingard JR, Majhail NS, Bajorunaite R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, RIZZO JD,Bolwell BJ, Socié G. Long-term survival and late deaths in 2-year survivors of myeloablativeallogeneic hematopoietic-cell transplantation for hematologic disorders. Blood 114:215, 2009.

36. Hahn T, McCarthy PL, Hassebroek A, RIZZO JD, Parsons S, Joffe S, Majhail N. Transplant utilization,procedure patterns and patient characteristics in North American transplant centers from 1994-2005.Biol Blood Marrow Transplant 16:S198-S199, 2010.

37. Loren AW, Wang Z, Chow E, Jacobsohn DA, Gilleece M, Halter J, Joshi S, Sorror ML, Bolwell BJ,Wingard J, Socié G, RIZZO JD, Majhail NS. Pregnancy after hematopoietic-cell transplantation: areport from the late effects committee of the Center for International Blood and Marrow TransplantResearch. Biol Blood Marrow Transplant 16:S176, 2010.

38. Akpek G, Pasquini MC, Agovi MA, Logan B, Cooke KR, Maziarz RT, Gupta V, Lazarus HM, Hale GA,Marks DI, Maharaj D, Popat U, Carabasi M, Bornhaeuser M, Bolwell BJ, Ringden O, Ballen KK,RIZZO JD, McCarthy PL, Ho VT. Spleen status and engraftment after allogeneic hematopoietic stemcell transplantation. Blood 116:1432-1433, 2011.

39. Majhail NS, Bajorunaite R, Sobecks RM, Wang Z, Jacobsohn DA, Sorror ML, Bolwell BJ, Wingard JR,RIZZO JD, Socié G. Second solid cancers after allogeneic hematopoietic-cell transplantation usingbusulfan-cyclophosphamide conditioning. Biol Blood Marrow Transplant 16:S176-S177, 2010.

40. Ballen KK, Klein JP, Pedersen TL, Kurtzberg J, Lazarus HM, LeMaistre CF, Mehta P, Palmer J, SetterholmM, Wingard JR, Joffe S, Parsons SK, Switzer GE, Lee SJ, RIZZO JD, Majhail NS, and for the HealthPolicy Working Committee of the CIBMTR. Relationship of race/ethnicity and survival after singleumbilical cord blood transplantation. Blood 116:104-105, 2010.

41. Hahn T, McCarthy PL, Hassebroek A, Klein JP, RIZZO JD, Parsons S, Joffe S, Majhail NS. Significantimprovement in day 100 and 1-year overall survival in patients who underwent myeloablativeallogeneic hematopoietic cell transplant in the US or Canada between 1994 and 2005. Blood 116:1442,2010.

42. Majhail NS, Quinn G, Brazauskas R, Wang Z, Chow E, Gilleece M, Halter J, Joshi S, Pidala J, Bolwell B,Jacobsohn D, Socie G, Sorror M, Wingard JR, RIZZO JD, Loren A. Transplant physician perceptionsand practice patterns regarding fertility preservation in hematopoietic-cell transplant (HCT) recipients.Biol Blood Marrow Transplant 17: S240, 2011.

43. McCarthy PL, Hahn T, Hassebroek A, Klein JP, RIZZO JD, Parsons S, Joffe S, Majhail NS. Significantimprovement in overall survival in patients who underwent autologous hematopoietic cell transplant inthe US or Canada between 1994 and 2005. Blood 116:990, 2011.

44. Stadtmauer EA, Krishnan A, Pasquini MC, Ewell M, Alyea EP, Antin JH, Castro-Malaspina H, Kassim AA,Negrin R, Qazilbash MH, RIZZO JD, Rowley SD, Sahebi F, Somlo G, Vesole DH, Vogl DT, WeisdorfDJ, Geller N, Horowitz MM, Maloney DG, Giralt S. Tandem autologous stem cell transplants with orwithout maintenance therapy versus single autologous transplant followed by HLA-matched siblingnonmyeloablative allogeneic stem cell transplant for patients with high risk multiple myeloma: resultsfrom the BMT CTN 0102 Trial. Blood 116:233-234, 2011.

45. Picozzi V, J Releford J, Faure M, Eastwood D, RIZZO JD. The value of the hematologist: appropriate use ofdiagnostic endoscopy in microcytic and normocytic anemias (MNA). Blood 118:342a, 2011.

46. McClune B, Pedersen TL, Ahn KW, Warlick ED, Pidala J, Waller EK, RIZZO JD, Cairo MS, Woolfrey A,Artz A, Lazarus HM, Weisdorf DJ. Reduced intensity or non-ablative hematopoietic celltransplantation in older patients with non-Hodgkin lymphoma (NHL): encouraging survival for

27 / 30

patients ?55 years. Blood 118:1015a, 2011.47. Weisdorf DJ, Zhang MJ, Arora M, RIZZO JD, Horowitz MM, Eapen M. Graft-versus-host disease (GVHD)

induced graft-versus-leukemia (GVL) effect: more impact on later relapse and disease-free survivalfollowing reduced intensity conditioning. Blood 118:1014a, 2011

48. Bredeson C, Burkart J, Zhu X, Sun Y, LeRademacher J, Pasquini M, Armstrong E, RIZZO JD, Kato K.Chimerism testing with reduced intensity intravenous Busulfan-based conditioning regimens: once isenough. Biol Blood Marrow Transplant 18:S331-S332, 2012.

49. Bredeson C, Burkart J, Sun Y, Zhu X, LeRademacher J, RIZZO JD, Armstrong E, Pasquini M, Kato K.Dose, schedule and PK practices with IV busulfan-based conditioning regimens in a non-inferioritytrial: heterogeneous practices but low VOD and TRM. Biol Blood Marrow Transplant 18:S325, 2012.

50. Pederson KA, RIZZO JD, Hahn T, Lee SJ, McCarthy PL, Ammi MS, Denzen EM, Drexler R, Flesch SM,James H, Omondi NA, Pedersen TL, Murphy EA, Majhail NS. Patient and Family Out-of-PocketCosts of Allogeneic Hematopoietic Cell Transplantation (HCT): A Pilot Study. Biol Blood MarrowTransplant 18:S237-S238, 2012.

51. Cornell RF, Thompson J, Drobyski WR, Fenske TS, Horowitz MM, Palmer JM, Pasquini MC, Saad AA,RIZZO JD, Saber W, Zhang M-J, Zhong X, Hari P. Risk factors and clinical features of autologousgraft-versus-host disease/engraftment syndrome after autologous hematopoietic cell (HCT)transplantation. Biol Blood Marrow Transplant 18:S250, 2012

52. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio M, Maziarz RT, Antin JH, Soiffer RJ,Weisdorf DJ, RIZZO JD, Horowitz MM, Saber W. Validation and Refinement Of The Disease RiskIndex For Stratification Of Patients Undergoing Allogeneic Stem Cell Transplantation: A Study Of13,131 Patients From The Center For International Blood & Marrow Transplant Research. Blood122:548, 2013

53. Lee SJ, Le-Rademacher J, Jim H, Syrjala KL, Wingard JR, Logan BR, Wu J, Majhail NS, Wood WA,RIZZO JD, Geller NL, Kitko CL, Faber Jr EA, Abidi MH, Slater SE, Horowitz MM, Jacobsen P.Exercise and Stress Management Training For Patients Undergoing Autologous Or AllogeneicHematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical TrialsNetwork BMT CTN 0902. Blood122: 699, 2013

54. Majhail NS, Payton T, Mau LW, Le-Rademacher J, Chitphakdithai P, Ekrich M, Joffe S, Lee SJ, LeMaistreCF, Loberiza Jr FR, Logan BR, Murphy EA, Parsons SK, Repaczki-Jones R, RIZZO JD, Robinett P,Denzen E. Provider and Center Characteristics Of US Transplant Centers and Their Association WithSurvival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From aNational Survey Conducted By The Center For International Blood and Marrow Transplant Research(CIBMTR). Blood 122:1687, 2013

55. Pulsipher MA, Chitphakdithai P, Logan BR, Switzer GE, Riches M, Moffitt HL, RIZZO JD, Anderlini P,Leitman SF, Vaarni JW, Hays A, Kobusingye H, Miller jp, Drexler RJ, King R, Horowitz MM, ConferDL, Navarro WH. Related PBSC Donors Age > 60 Have High Rates of Baseline and Donation-RelatedPain and Slow Recovery: First Report from the Related Donor Safety Study (RDSafe). BMT TandemMeetings, Dallas TX, USA, March 2014.

56. Kroll TM, Singavi A, Schmidt W, Eastwood D, Drobyski W, Horowitz MM, Palmer J, Pasquini M, RIZZOJD, Saber W, Parameswaran NH, Fenske T. Safety of Outpatient Autologous Hematopoietic CellTransplantation (AuHCT) for Multiple Myeloma and Lymphoma. BMT Tandem Meetings, Dallas TX,USA, February 2014.

57. Pollack J, Schaper K, Renner R, Martinez C, Sorensen S, Milius B, O’Neill C, Jones RB, RIZZO JD.Extending the Bridg Model with Hematopoietic Cell Transplant Concepts. BMT Tandem Meetings,Dallas TX, USA, February 2014.

58. Saber W, Cutler C, Nakamura R, Zhang MJ, Atallah E, RIZZO JD, Maziarz RT, Cortes JE, Kalaycio M,Horowitz MM. Comparison of Outcomes After Related and Unrelated Hematopoietic CellTransplantation in Adults with Myelodysplastic Syndromes: A Report From the Center forInternational Blood and Marrow Transplant Research (CIBMTR). Blood 120:355a, 2012

59. Pasquini MC, Logan BR, Ho VT, McCarthy, PL Jr., Cooke KR, RIZZO JD, Zhu X, Sorror ML. ComorbidityIndex (CI) in Autologous Hematopoietic Cell Transplantation (HCT) for Malignant Diseases:Validation of the HCT-CI. Blood 120:814a, 2012

60. Sorror ML, Logan BR, Zhu X, RIZZO JD, Cooke KR, McCarthy, PL Jr., Ho VT, Storer B, Pasquini MC.Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation ComorbidityIndex (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood andMarrow Transplant Research (CIBMTR) Study. Blood 120:733a, 2012

28 / 30

61. Thakar MS, Logan BR, Pasquini MC, McCarthy PL Jr, Ho VT, Cooke KR, Zhu X, RIZZO JD, Sorror ML.The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Can Prospectively DiscriminateRisks Affecting Overall Survival in Pediatric and Adult Patients with Non-Malignant Diseases. Blood120:737a, 2012

62. Eckrich MJ, Le-Rademacher J, RIZZO JD, Baker KS, Bhatla D, Buchbinder DK, Cooke KR, Duerst R,Gilman A, Frangoul H, Kapoor N, Kernan NA, Verneris M, Eapen M. The Effect of Transplant CenterCharacteristics on Survival After Pediatric Hematopoietic Cell Transplantation. Blood 120:762a, 2012

63. Atallah E, Pedersen TL, Warlick ED, Dircks A, Weisdorf D, Horowitz MM, RIZZO JD. The Outcome ofHematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) in Adults >=65Years of Age: First Report of the Coverage with Evidence Development (CED) in MedicareBeneficiaries. Blood 120:1983a, 2012

64. Bredeson C, Le-Rademacher J, Zhu X, Burkart J, Kato K, Armstrong E, Sun Y, Smith A, Ho VT, McCarthyPL, Cooke KR, RIZZO JD, Pasquini MC, Improved Survival with Intraveneous Busulfan (IV BU)Compared to Total Body Irradiation (TBI)-Based Myeloablative Conditioning Regimens: A CIBMTRProspective Study. BMT Tandem Meetings, Salt Lake City, UT, USA, February 2013

65. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio M, Maziarz RT, Antin JH, Soiffer RJ,Weisdorf DJ, RIZZO JD, Horowitz MM, Saber W. Validation and Refinement Of The Disease RiskIndex For Stratification Of Patients Undergoing Allogeneic Stem Cell Transplantation: A Study Of13,131 Patients From The Center For International Blood & Marrow Transplant Research. Blood122:548, 2013

66. Knight JM, RIZZO JD, Logan BR, Wang T, Cole SW, Altered Genetic Transcription Profiles amongHematopoietic Stem Cell Transplant Recipients based on Socioeconomic Status. Invited oral paperpresentation, American Psychosomatic Society, San Francisco, CA (3/2014)*Selected for press release

67. Knight JM, RIZZO JD, Logan BR, Wang T, Cole SW, Altered Genetic Transcription Profiles amongHematopoietic Stem Cell Transplant Recipients based on Socioeconomic Status. Oral paperpresentation, Society of Biological Psychiatry, New York, NY (5/2014)

68. Wood W, Le-Rademacher J, Fei M, Logan BR, Syrjala K, Majhail NS, Wingard JR, Abidi MH, Geller NL,Wu J, RIZZO JD, Faber E, Jim H, Jacobsen PB, Horowitz MM, Lee SJ. Patient-Reported Quality ofLife Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: ASecondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)0902. Blood 124:206a, 2014.

69. Seftel MD, Neuberg D, Zhang MJ, Wang HL, Bergeron J, Couban S, DeAngelo DJ, de Lima MJ, DevineSM, Eapen M, Horowitz MM, Pasquini MC, RIZZO JD, Saber W, Sallan SE, Sandmaier BM,Weisdorf DJ. Superiority of Pediatric Chemotherapy over 37 Allogeneic Hematopoietic CellTransplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: ACombined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. Blood 124:319a, 2014.

70. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Switzer GE, Riches ML, RIZZO JD, Anderlini P,Leitman SF, Varni JW, Hays A, Kobusingye H, Besser RM, Miller JP, Drexler RJ, King RJ, HorowitzMM, Navarro WH, Confer DL. Baseline Symptoms, Female Sex, and Younger Age Are Correlatedwith Higher Levels of Peri-Collection Pain, Symptoms, and Persistent Discomfort One Year afterRelated Donor BM and PBSC Donation: An Analysis of the Related Donor Safety Study (RDSafe).Blood 124:3847a, 2014.

71. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai PR, Switzer GE, Riches ML, RIZZO JD, Anderlini P,Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP Drexler RJ, King RJ, Horowitz MM,Confer DL. Related PBSC Donors Experience Higher Levels of Pain and Donation-Related Symptomsand Less Complete Rates of Recovery Compared to Unrelated Donors: Primary Analysis of theRelated Donor Safety Study (RDSafe). (Oral) Biol Blood Marrow Transplant, 21:S41 - S42, 2015.

72. Knight J, Cole S, Logan BR, Wang T, RIZZO JD Clinical Outcomes Among Unrelated Donor TransplantRecipients for Acute Myelogenous Leukemia As a Function of Socioeconomic Status and RelatedTranscriptome Differences. (Oral) Biol Blood Marrow Transplant, 21:S76 - S77, 2015.

73. Denzen EM, Murphy EA, Baker KS, Abetti B, Jahagirdar B, Kamani NR, RIZZO JD, Saber W, Salazar L,Schatz BA, Syrjala KL, Wingard JR, Majhail NS. Patient and Provider Preferences for SurvivorshipCare Plans for Allogeneic Hematopoietic Cell Transplantation (HCT) Survivors: A Qualitative Study.(Oral) Biol Blood Marrow Transplant, 21:S174 - S175, 2015.

74. Dhakal B, Martens M, Kapke J, D'Souza A, Pasquini MC, Saber W, Hamadani M, Drobyski W, RIZZO JD,Horowitz MM, Zhang MJ, Hari PN. Outcomes of Allogeneic Hematopoietic Cell Transplantation(AHCT) for Multiple Myeloma (MM): Impact of Disease Risk and Conditioning Regimen. (Oral) Biol

29 / 30

Blood Marrow Transplant, 21: S278 - S279, 2015.75. Ehrhardt MJ, Brazauskas R, He W, RIZZO JD, Shaw BE, Survival of patients who develop solid tumors

following hematopoietic stem cell transplantation. Paper Presentation, 14th International Conferenceon Long-Term Complications of Treatment of Children and Adolescents for Cancer, Arlington VA,June, 2015.

76. Knight JM, Martens M, Syrjala KL Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim H,Wingard JR, Horowitz MM, Majhail NS, Abidi MH, Geller NL, Fei M, Wu J, RIZZO JD. Pre-transplant health-related quality of life factors as predictors of outcomes following hematopoietic celltransplantation: A study from the BMT CTN 0902 trial. Oral Presentation, 2015 World Congress ofPsycho-Oncology, Washington, DC, USA, July 28 – August 1, 2015.

77. Syrjala KL, Sutton SK, Yi JC, Jim HSL, Knight JM, Wood WA, Jacobsen PB, Majhail NS, Abidi MH,Wingard JR, Horowitz MM, Rizzo JD, Le-Rademacher J, Wu J, Lee SJ. Cancer and TreatmentDistress Measurement over Time in a Multicenter Cohort of Hematopoietic Cell Transplantation(HCT) Recipients (BMT CTN 0902). Psycho-Oncology, 2015, 24 Suppl 2:84-85.

78. Knight J, Martens M, Syrjala K, Le-Rademacher J, Logan BR, Lee S, Jacobsen P, Wood W, Jim H, WingardJ, Horowitz M, Majhail N, Abidi M, Geller N, Fei M, Wu J, Rizzo JD. Pre-transplant health-relatedquality of life factors as predictors of outcomes following hematopoietic cell transplantation: A studyfrom the BMT CTN 0902 trial. Psycho-Oncology, 2015, 24 Suppl 2:99.

79. D'Souza A, Millard HR, Knight JM, Brazauskas R, Vogel J, Mattila D, Flynn K, Lee SL, Horowitz MM, Rizzo JD, Shaw BE. Patient-Reported Sleep Quality at Baseline Correlates with 1-Year Survival afterAllogeneic Hematopoietic Cell Transplantation in Adults. Blood 2017 130:3447.

80. Chhabra S, Hari P, Visotcky A, Shah NN, Rizzo JD, Saber W, D'Souza A, Dhakal B, Anshu A, ThompsonR, Fenske TS, Shaw BE, Drobyski WR, Pasquini MC, Hamadani M. Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation(alloHCT): Preliminary Results of a Phase I/II Study. Blood 2017 130:1974

81. Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Hillard CJ, Rizzo JD, Raison CL, D’Souza A, Coe CL,Drobyski WR. Inflammation and the brain: tocilizumab may redefine our understanding of depressionand related symptoms in the medically ill. Oral Paper Presentation, Academy of Consultation LiaisonPsychiatry, Orlando, FL (11/2018)

82. Knight J.M., Rizzo JD. Hari P., D’Souza A., Logan B.R., Giles K.E., Hamadani M., Chhabra S., Dhakal B.,Shah N., & Cole S.W. (2018) Translational psycho-oncology: Neurally regulating cancer throughpropranolol by inhibiting stress-related gene expression profiles associated with adverse canceroutcomes. Academy of Consultation Liaison Psychiatry. Orlando, FL. November 16, 2018.

Non-Peer Reviewed Educational Products1. Jim HSL, Syrjala KL, RIZZO JD. Supportive care of hematopoietic cell transplant patients. Biol Blood

Marrow Transplant 18:S12-S16, 2012.

Powered by TCPDF (www.tcpdf.org)

30 / 30

http://www.tcpdf.org

J. Douglas Rizzo MD, MS Curriculum Vitae CV

Documents

Transcript of J. Douglas Rizzo MD, MS Curriculum Vitae CV